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ABSTRACT OF DISSERTATION 
 
 
EVALUATING RETENTION TO HIV MEDICAL CARE AND ITS IMPACT ON THE HEALTH 
OUTCOMES OF INDIVIDUALS LIVING WITH HUMAN IMMUNODEFICIENCY VIRUS 
 In the last few years, engagement in medical care among individuals living with HIV 
has become a major priority among HIV medical providers and public health researchers. 
Engagement in medical care is an important concept as it involves the process of linking 
newly diagnosed individuals into medical care and retaining those individuals in care 
throughout the course of their infection. Although there have been major advances in the 
management of HIV, like the advent of Highly Active Antiretroviral Therapy, morbidity and 
mortality due to HIV cannot be fully reduced if the individual does not optimally retain in 
care. Retention in HIV medical care has become an emerging topic in HIV research, but 
there still remains a scarce amount of research on how to properly define retention, 
understand its predictors, and how it impacts HIV outcomes. 
 The purpose of this dissertation was to evaluate retention in HIV medical care 
among individuals diagnosed with HIV and seeking care at an urban infectious disease clinic 
in Kentucky. The three specific aims of this dissertation were to: (1) compare methods in 
measuring retention in HIV medical care; (2) determine the predictors of poor retention in 
care and assess the effect of non-HIV related comorbidities have on retention over time; and 
(3) determine the impact early retention to medical care has on time to viral load 
suppression and rebound among individuals initiating Highly Active Antiretroviral Therapy. 
 A retrospective cohort study was conducted employing a medical chart review, and 
patients who sought HIV care at the Bluegrass Care Clinic between January 1st 2003 and 
May 1st 2011 were eligible for the study. There were 1,358 patients included in the study 
and these individuals were followed until December 31st, 2011.  
 The results suggested that individuals living with HIV should seek care at least once 
every six months (visit constancy) and that only 48.6% of the study population obtained 
optimal retention over time. Over time the rate of retention decreased among the study 
sample and those with optimal retention were more likely to suppress their viral loads 
compared to poor retainers. 
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CHAPTER ONE 
Introduction 
Due to advances in the clinical management of individuals infected with Human 
Immunodeficiency Virus (HIV), most notably the advent of Highly Active Antiretroviral 
Therapy (HAART), the HIV medical community has witnessed dramatic reductions in 
morbidity and mortality from HIV infection.1-4  HAART has been shown to improve CD4+ cell 
counts as well as improve the chance of sustaining HIV RNA plasma viral loads (VL) below 
50 copies per milliliter.2,3,5  The use of HAART has also been shown to reduce the rate of 
hospitalizations, opportunistic infections, Acquired Immune Deficiency Syndrome (AIDS), 
and death.2-8  One study conducted by Walensky et al, estimated that at least 3 million years 
of life have been saved in the United States (U.S.) since the introduction of HAART.2 
However, clinical management of HIV can only be successful if individuals infected with HIV 
are identified and linked to medical care early, and retained in medical care.9  It is estimated 
that over a million individuals in the U.S. are living with HIV, and roughly 21% of them are 
unaware of their infection 10-12 and approximately 31% of newly diagnosed individuals 
delay linkage to HIV medical care for 6 months or longer. 13   
Even with the early identification of HIV infection and initial linkage to care, optimal 
retention in HIV medical care is desirable to ensure full access to treatment benefits. It is 
extremely important for individuals living with HIV to have consistent contact with their 
HIV medical provider, regardless of whether or not the individual has initiated HAART. An 
individual, who has not yet initiated HAART, needs consistent contact with their HIV 
medical provider so disease progression can be monitored and HAART can be initiated 
when appropriate. Individuals, who have already initiated HAART, need consistent contact 
with their medical providers to monitor the effects of HAART, assess for complications, and 
ensure the risk of drug resistance is reduced.9,14,15  
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Linkage to care and retaining individuals living with HIV in medical care have become a 
persistent challenge among HIV medical providers and has become a major priority for both 
medical providers as well as public health organizations.13,14 The Centers for Disease 
Control and Prevention (CDC) estimate that roughly one-third of diagnosed individuals are 
not receiving care (linkage)11 and it has been estimated that approximately 25 – 30% of 
individuals who initiate outpatient HIV medical care, do not retain in care after one 
year.12,16,17  
Retention in care is a major problem for HIV care providers because it does not allow 
individuals living with HIV to be properly monitored during the course of their 
infection.14,15,18-20 Individuals who fail to retain in care miss their opportunity for timely 
initiation of HAART, treatment adherence support, and monitoring of CD4+ cell counts and 
VL response.14,15,19,21,22 The Department of Health and Human Services (DHHS) recommends 
individuals newly diagnosed and linked into care have their CD4+ cell counts and VLs 
observed every 3 to 4 months until their clinical response is stable.23 Studies have shown 
that individuals who have poor retention in care have a higher risk of VL and CD4+ cell 
count failure21,24-26, and risk acquiring AIDS defining illnesses (ADIs)27, and death21,27-29 
compared to those individuals who have optimal retention in care. One study conducted by 
Giordano et al., estimated that individuals with poor retention compared to those with good 
retention (at least one clinic visit every 6 months) were almost 2 times more likely to die.28 
From a public health perspective, it is important to retain individuals in HIV medical care, as 
this may alleviate complications related to AIDS and promote behavior changes which could 
possibly reduce the risk of HIV transmission.14-16,21,30,31 
Over the past few years, retention in HIV medical care has been given significant 
attention from the HIV research and clinical community, and has been recognized as a vital 
part in optimizing individuals’ outcomes.13-15 Although there is an emergence of interest in 
 
3 
 
this topic, there still remains a scarcity of research. Continuous engagement in HIV care 
without any interruption of access to HAART and other treatment is the main premise of 
retention.14,21,32 One major challenge for clinicians and researchers who are interested in 
studying retention in care is deciding on how to best measure retention. Like adherence to 
medication studies, retention in care has multiple measurement techniques that can be used 
for determining retention in care.13-15 The challenge is deciding which retention measure to 
use and which measure most accurately predicts HIV clinical outcomes like VL suppression, 
CD4+ cell count failure, and AIDS progression.   
Measuring retention in care can be difficult in some research and clinical settings due to 
the dynamic nature of HIV clinical cohorts. According to a small number of researchers in 
this field, there are approximately five retentions in HIV clinical care measures (gaps in 
care, missed visits, visit adherence, visit constancy, and the Health Resources and Services 
Administration HIV/AIDS Bureau (HRSA) performance measurements). There is no clear 
preferred standard.13-15 It is important for researchers, in this field, to have a lucid idea of 
which retention measure is appropriate for their cohort, as well as which measure will 
more accurately predict specific clinical outcomes.  
Although most studies have established predictors of poor retention in care and how 
poor retention may affect certain clinical outcomes, these studies have focused on only one 
retention measure and employed a short follow-up period (≤3 years).9,22,27,33,34 To our 
knowledge, no study has attempted to compare multiple retentions in care measures and 
determine which measure most accurately predicts clinical outcomes like VL suppression 
and CD4+ cell count failure.  The purpose of this dissertation is to evaluate retention in HIV 
medical care, observe how retention changes over time, and understand the association 
between poor retention and poor HIV clinical outcomes. The three specific aims of this 
dissertation are to: 
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1. Compare three different retentions in care measures and evaluate the 
association between optimal to poor retention and immunological and 
virological outcomes. 
2. Determine the predictors of poor retention and assess the effect non-HIV related 
comorbidities have on retention over time. 
3. Employ parametric time to event methods to determine the effect poor 
retention has on time to viral suppression and viral rebound, among patients 
who have initiated HAART.  
It is hypothesized that those individuals who do not retain in care consistently throughout 
the course of their infection will be more likely to have a CD4+ cell count failure, less likely 
to have a viral suppression, and more likely to have a viral rebound compared to those 
individuals who do retain in care. The remaining sections of this dissertation will be divided 
into five chapters. The chapters in this dissertation will help guide clinicians and public 
health researchers in defining retention in care, identifying predictors of poor retention, 
and developing ways to improve viral suppression.  
The purpose of chapter two, “Measuring Retention in HIV Medical Care: A Literature 
Review,” was to assess the different methods used by clinicians and researchers to define 
retention in medical care among individuals living with HIV. The chapter described five 
different retention measurement techniques: visit constancy, missed visits, visit adherence, 
gaps in care, and the HRSA performance measure. The chapter focused on defining each 
retention measure, describing the advantages and disadvantages of employing each 
measure, and presenting data from studies that observed these measures. There is no 
standard method in defining retention in care, but the predictors for poor retention appear 
to be similar across studies and it appears to impact clinical outcomes.    
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In chapter three, “A Comparison Study of Methods for Measuring Retention in HIV 
Medical Care,” results of a study to compare methods used for measuring retention in 
medical care are presented. Three methods in measuring retention in care (visit constancy, 
gaps in care, and the HRSA performance measure) were evaluated and compared to one 
another. Using receiver operating characteristic curves, retention measures were compared 
based on their ability to predict individuals with a suppressed VL and CD4+cell count 
failure. To our knowledge, this is one of the first studies to compare retention measures’ 
ability to determine viral suppression and CD4+ cell count failure. A medical chart review 
was conducted and 1,358 patients were abstracted from the records and included in the 
analysis. The results from this chapter can be used to guide clinicians in choosing the 
appropriate retention measure.  
The fourth chapter, titled “Impact of non-HIV Related Comorbidities on Retention in 
HIV Medical Care: Does Retention Improve over Time,” presents results on a study that was 
conducted to identify predictors of retention in care as well as determining how factors like 
non-HIV related comorbidities and ADIs impact retention over time. Researchers studying 
retention have generally restricted their study time periods to 1 to 3 years. There is a lack of 
research on how retention in care affects the population over time. In particular how factors 
like non-HIV related comorbidities impact retention over time. Using visit constancy as the 
retention measure, the patient population included in this retrospective cohort study was 
followed for a mean of 5.75 years. A multinomial regression was used to determine 
predictors of the retention groups and generalized linear mixed models were used to 
determine whether retention in care improved over time.  
The fifth chapter, titled “Impact of Retention in HIV Medical Care on Time to Viral 
Load Suppression and Rebound among Individuals Initiating HAART,” presents the results 
on the study conducted to determine how retention in care impacts time to viral 
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suppression and time to viral rebound. Initiating HAART has been shown to improve the 
chances of viral suppression, but little research has been conducted to assess the impact 
retention has on viral suppression once an individual has initiated HAART. Also, once an 
individual has achieved viral suppression, it is unknown how retention in care impacts the 
risk of viral rebound. Using parametric survival methods, the association between retention 
in care and time to viral suppression/rebound was assessed.  
The sixth chapter concludes the dissertation. The chapter summarizes the findings 
presented in the previous chapters and discusses the implications on the individual as well 
as the public health prevention efforts. Recommendations for future research is presented 
in this chapter as there is still research to be done on retention in HIV medical care and 
strategies need to be developed and set in place to re-engage those individuals who have 
been lost to follow-up. 
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CHAPTER TWO 
Measuring Retention in HIV Medical Care 
A Literature Review 
Background 
Since the initiation of HAART into the clinical management of HIV, it has now been 
considered a manageable chronic disease by reducing the morbidity and mortality related 
to HIV.5-7 Clinical and public health researchers have all demonstrated the significant 
benefit obtained by initiating HAART, but individuals can only obtain these benefits if they 
maintain consistent contact with their medical provider.35,36 Engaging and retaining 
individuals living with HIV into medical care is extremely important and has become a 
major problem as patient dropout is common.17,18,21 It is pertinent to diagnose individuals 
with HIV and link them into care early as well as engage them in regular and consistent care 
with their medical provider to maintain optimal health.19,21 This test and treat approach has 
become an important step in making sure that individuals with HIV are managing their 
disease properly.12 
 Consistent contact with an HIV medical provider ensures that the individual will 
initiate the appropriate therapy on time and will be monitored regularly to maintain 
suppressed viral loads and reduce the risk of progression to AIDS.13 It has been estimated 
that approximately 40% of patients do not retain in medical care, and this is a significant 
public health issue as it has been shown that optimal retention in care can suppress the 
replication of HIV, thereby reducing the risk of transmission of HIV to others.13,31 
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In order to achieve optimal health outcomes in persons infected with HIV, optimal 
retention must be maintained throughout the course of infection. HIV requires a lifelong 
commitment and treatment regimen, and it is important for clinicians to retain their 
patients in medical care and alleviate patient fatigue. The Department of Health and Human 
Services (DHHS) guidelines states that individuals initiating HAART should receive care 
every three months until VL has been suppressed and then every four to six months after 
suppression of the VL.23 These recommended guidelines allow the individual to have their 
VL and CD4+ cell counts to be monitored and appropriate treatment administered whether 
it is HAART or opportunistic infection prophylaxis.23 
Similar to medication adherence studies, determining the methods needed to define 
retention can be difficult and may rely on the data and resources the clinic or research 
group has available.13-15 There are multiple methods used in measuring retention, but there 
is currently no preferred method.15 Researchers in this field of study have published many 
approaches in defining retention in care and have determined the predictors for each 
retention measure. It is essential to provide a clear framework for how retention is defined 
and measured is something that is essential to retention in care research.14  
The purpose of this chapter is to provide an extensive review of the multiple 
approaches commonly used to study retention in care among individuals living with HIV. 
The goals of this review are to: 1. Define all retention in care measurements; 2. Describe the 
advantages and disadvantages of each measure; 3. Describe the established predictors of 
retention in care; and 4. Discuss the effects poor retention has on HIV clinical outcomes. The 
review concludes with a discussion of where we are now in this area of research and what 
this dissertation will add to the current literature. 
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Methods 
 Electronic databases (Pubmed, CINAHL, Embase, and Medline) were searched for 
appropriate literature published between 1997 and 2011. This time period was chosen 
because it ensured that the individuals in these studies had the opportunity to initiate 
HAART. The search included the following combined keywords: 1. HIV/AIDS; 2. Retention; 
3. Missed clinic visits; 4. Gaps in care; 5. Utilization of Care; 6. Suppression and Rebound; 7. 
Adherence; 8. Survival; and 9. Comorbidities. Secondary searches were conducted by 
checking the reference lists of the articles obtained from the primary search. Selected 
articles were restricted to the following time frame: 1997 and 2011, and only articles 
published in English were accepted. 
Retention in Care Measurements 
 Retention in care studies have been an emerging topic in HIV care research and  
researchers have published multiple studies describing retention in care, the predictors of 
poor retention, and the effects poor retention has on clinical outcomes.14-16,21,22,24,27,33,37-43 
Unfortunately, because there is no preferred method for defining poor retention in care, 
researchers have used multiple definitions for measurements of retention, allowing 
comparison of studies to be difficult.15 Due to the growing interest in this research topic, a 
few reports have been published summarizing several of the retention measurements.13-15  
The selection of a retention measure may be based on a number of factors which may 
include the purpose for measuring retention in care, the type of clinic visit data that are 
available, clinic scheduling practices, and computational issues.15 Retention in HIV medical 
care can be measured and conceptualized in at least five different ways: 
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1. Missed clinic visits 
2. Clinic visit adherence 
3. Gaps in Care 
4. Visit Constancy 
5. HRSA performance measure 
There is currently no ‘gold’ standard for measuring retention, and no research study to 
suggest which measure may be the best and most appropriate measure at defining 
retention. 
Missed Clinic Visits/ Clinic Visit Adherence 
 A straight forward retention in care measurement that is widely used by clinical and 
public health researchers is missed clinic visits.14,15 Regardless of the number of scheduled 
visits, this measure captures the number of missed visits during a specified time period and 
they are typically defined as the number of clinic visits missed (‘no show’) and do not 
include canceled or rescheduled visits in the  retention measurement.14,15  Multiple studies 
have used missed clinic visits as a measure of retention and are generally applied as either a 
dichotomous variable (yes/no)29,33,34,44,45 or a count (number of missed visits).27,46,47 
 Clinic visit adherence is a retention measurement that is derived from missed clinic 
visits and it involves the use of visits scheduled as well as visits missed or attended.15 Visit 
adherence can be defined as visit adherence or visit non-adherence.15 Visit adherence is a 
proportion that captures the number of completed visits in the numerator and the number 
of all scheduled visits in the denominator and is normally presented as percentage.15,35,46,48-
50 Visit non-adherence is similar to visit adherence, but instead of the number of completed 
visits in the numerator, the number of missed visits is used.15,35,45,46 
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 Mugavero et al. conducted a study in 2009 assessing missed visits and mortality in 
patients establishing initial outpatient HIV treatment.29 The authors conducted a 
retrospective study nested within a prospective HIV clinical cohort study which evaluated 
patients establishing initial outpatient treatment at the University of Alabama at 
Birmingham 1917 HIV/AIDS clinic between January 1st, 2000 and December 31st, 2005. 
Participants in the study were followed for one year after initial care visit and a missed visit 
was defined as a primary HIV care visit where the participant did not call the clinic to cancel 
or reschedule. ‘No Show’ visits, as Mugavero called them, were recorded as a dichotomous 
measure with participants dichotomized as no missed visits or ≥ 1 missed visit. Of the 543 
patients included in the study, approximately 60% of the cohort had at least one missed 
medical visit during the year of follow-up29. 
 Numerous researchers have employed missed clinic visits as their retention in care 
measurement, because of its simplicity.27,29,33-35,44-50 Missed clinic visits are easy to measure 
as it only involves the number of scheduled visits missed and does not involve timing 
between scheduled visits like the other measurements. Clinic visit adherence may be 
appropriate for research studies involving longer observation periods as this may allow for 
assessment of exposure/response relationships between retention and clinical 
outcomes.14,15 Also, missed clinic visit studies allow for clinicians to monitor individual 
patient behaviors.15  
A disadvantage in using missed visits as a retention measure is that missed clinic 
visits do not take into account individuals who are lost to follow-up, as individuals who are 
lost to follow-up and poorly retained in HIV medical care during a study period may be 
misclassified as clinic visit adherers’ even though they do not have any scheduled visits to 
miss.15 Clinics that use automatic rescheduling may over estimate the number of missed 
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visits and visit non-adherence as the patient contact information may not be updated and 
patients may not be aware of rescheduled visits. How to analyze cancelled clinic visits has 
become an issue for researchers in computing missed visits and visit adherence, as most 
researchers have removed missed visits due to cancellations from their 
calculation.14,27,29,44,50 The timing between the cancelled visit and rescheduled visit should be 
taken into consideration when calculating missed visit or visit adherence, so the issue of 
misclassification can be handled. 
Gaps in Care 
 Gap in care or loss to follow up is one other retention in care measurement that is 
relatively straightforward in measuring. This measurement involves only the clinic visits 
that were completed and the date for each clinic visit completed.15 The gap in care measure 
calculates a time interval between two consecutive visits, and is defined in 4, 6, or 12 month 
intervals and whether the individual exceeds that specified interval.15,17,38,40,43  Some studies 
have used ‘loss to follow up’ as a surrogate for gap in care, which is where the individuals 
who are seeking clinical care, drop out or have gaps greater than 12 or more months.38,43  
 A retrospective medical record analysis was performed in Harris County, Texas to 
measure the success with which patients newly entering outpatient care establish care. 
Scheduled and unscheduled clinic visits subsequent to the initial intake visit were 
abstracted from all medical records. The authors used gaps in care to describe the pattern of 
established care among those individuals living with HIV. The interval range between two 
visits was set at ≥6 months, and the patients who had a gap of 6 or more months between 
visits were defined as ‘poorly established’ in care. The authors also classified individuals 
who did not have any completed clinic visits after the initial intake as ‘not established’ (lost 
to follow-up) and those with multiple visits with gaps <6 months were classified as 
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‘established’ in care. Of the 404 patients included in the study, 48% had poor to no 
established care (11% were ‘not established’ and 37% were ‘poorly established). The 
authors were able to show that almost half of the study population was either poorly 
retained in care or completely lost to follow-up, meaning that their risk of severe illness had 
increased.51 
Similar to missed clinic visits, gaps in care is simple to compute, as you only need 
the dates of the completed visits and a difference between those dates (typically described 
in months).15 This retention in care measure involves only completed visits, so a researcher 
does not need to be concerned with obtaining the number of missed clinic visits or the 
issues with automatic rescheduling. The gap in care measure is a great measurement for 
monitoring individual patient behavior and can be used for administrative tracking of 
patients.15  
Although gaps in care are a fairly simple retention in care measure, it is not 
amenable for use as a time-varying covariate, so it may not be appropriate to use for longer 
observational studies. This could be due to the fact that you are dealing with individuals 
who may drop out and not return for lengthy periods of time, making it difficult to 
determine change in visit adherence over time. Gaps in care are a fairly crude measure, 
typically described as a dichotomous measure, and the appropriate length of a gap varies 
among studies.15 A potential bias that may occur in employing only the gap in care retention 
measure is misclassification. If an individual completes at least two visits and the interval is 
within the specified gap (e.g. 6 or 12 months), they would be considered to have optimal 
care even though they may not have any more scheduled visits and become lost to follow 
up. This is an issue that researchers should consider when deciding to use gaps in care as 
the preferred retention in care measure. 
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Visit Constancy 
 Aside from missed clinic visits, visit constancy has become a widely used 
measurement in HIV retention studies.13,15,21,22,28,36,42,43,52-57 Visit constancy is a retention 
measurement that observes the proportion of time intervals with at least one completed 
clinic visit.15 Because treatment guidelines recommend that individuals complete laboratory 
assessments and clinic visits every 3 to 6 months, time intervals in the visit constancy 
studies have typically ranged between 3 and 6 months.23 Most studies observe visit 
constancy as at least one clinic visit every 6 months for a specified time period (e.g. 1 year, 2 
years, etc.).21,22,52,53,57 
In 2011, Tripathi et al. conducted a retrospective study to determine rates of 
retention after initial linkage to care was established, in a cohort of newly diagnosed HIV –
infected persons in South Carolina and to characterize factors associated with lower 
retention after initial entry into HIV care. The individuals included in the study were 
followed for two years, observed in 6 month intervals (total of 4 intervals), and categorized 
into four types of retainers in HIV medical care: 1) Optimal Care – at least one visit in four 
out of the four 6-month intervals; 2) Suboptimal Care - at least one visit in three out of four 
6-month intervals; 3) Sporadic Care – at least one visit in two out of four 6-month intervals; 
and 4) dropout – no visits recorded over the 2 year interval. Of the 2,247 newly diagnosed 
individuals who initiated care during the observation period, 50% had optimal retention 
and 22% and 10% were sporadic retainers and dropouts, respectively. Tripathi was the first 
to categorize patients based on the number of 6 month intervals with a completed clinic 
visit.21 
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Visit constancy has become a widely used retention measure because it captures the 
number of visits an individual has completed within a specified time interval and it can be 
easily employed for use as a time-varying measure analytically.15 Visit constancy is a great 
measure for longer observational periods as researchers can attempt to assess an 
exposure/response relationship between poor retention and clinical outcomes, and can 
provide medical providers with treatment recommendations and suggestions on 
interventions.15 An advantage of visit constancy is that the measurement only requires 
completed clinic visits and does not require the use of missed clinic visits in the calculation, 
which could be difficult to obtain for settings that do not capture that information. 
Compared to gap in care, missed visits, and visit adherence, visit constancy is better 
equipped to account for lost to follow-up as these individuals will be considered 
dropouts.15,21  
Compared to the other retention measures, visit constancy is more computationally 
challenging and determining the appropriate intervals may pose difficulties as this may 
differ based on the patient’s disease severity. Determining whether the time interval (e.g. 3-
6 months) is based on calendar time (every individual has the same interval dates) or each 
individual’s unique interval date, which may be based on factors like the initial start date 
into care or initial start date of HAART, may pose more computational and programmatic 
difficulty.14,15 
HRSA performance measure 
 The HRSA performance measure is a relatively new retention in care measurement, 
and it observes whether an individual completed 2 or more clinic visits with each visit 
separated by 3 or more months in time during a 12-month study period.15,39,58 The 
performance measure is considered a hybrid measure as it incorporates elements of visit 
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constancy and gaps in care.15  The HRSA performance measure is typically used by clinic 
administrators to determine performance relative to the clinic standards that have been 
recommended by the DHHS.15,23,58 
 Researchers have discussed the use of this measure as more of a performance 
measure (i.e. how well the specified clinic is keeping patients engaged in care) to help guide 
clinicians in developing interventions to increase retention. The measure can be used for 
clinic level quality assurance as well as administrative tracking and reporting.15 An 
advantage of this hybrid measure is that it does not involve the use of missed clinic visits 
and only needs to capture completed visits to calculate the measure. The HRSA performance 
measure also overcomes the limitation of appropriate interval length observed with the 
other measures like visit constancy.15,38,39,43 The performance measure is relatively 
straightforward, but is computationally complex, as it involves the timing of clinic visits. 
Researchers conducting studies in the retention in care area may not prefer to use the HRSA 
performance measure as it is not suitable for use as a time-varying measure.15  
 The HRSA performance measure has been endorsed by HRSA as well as the National 
HIV/AIDS Strategy (NHAS).58,59 A goal set by NHAS is to increase the proportion of people 
living with HIV who are retained in care from 73% to 80%.59 There have only been a few 
studies to include the HRSA performance measure as the retention in care 
measurement.38,39,43 In 2012, Hall et al observed retention in care among 13 U.S. areas using 
the HRSA performance measure, and approximately 45% of the people living with HIV in 
the 13 U.S. areas had at least two visits separated by three or more months.39 
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Predictors of Retention in Care 
 Although there are multiple ways in defining retention in care, the common goal 
among clinicians and researchers is to comprehend factors that play a role in poor retention 
and to promote methods to prevent poor retention from occurring. In 2010, Marks et al. 
conducted a meta-analysis to determine the overall percentage of individuals living with 
HIV who are poor retainers in medical care. The authors demonstrated that regardless of 
the length in time measured and the type of retention measurement used in these studies; 
approximately 40% of individuals were poor retainers in care.13 A national study conducted 
by Cohen et al, suggested that 49% of individuals linked into care were poor retainers in 
medical care.11 This is a disconcerting statistic and it has become an important priority to 
identify which patients are at greatest risk for not being retained in medical care. 
 In the retention in care literature, demographic and behavioral characteristics found 
to be associated with poor retention include black and Hispanic 
race/ethnicity21,28,29,33,35,40,46,50,52,56, younger age21,29,33,35,37,40,54, female gender36,54,  
heterosexual contact46, less education60, lack of health insurance or public health insurance 
(Medicaid)29,40,52,55, history of or current illicit drug use17,49,50,52,54,61, shorter duration of 
follow-up17, lower income 60, and unemployment.52,60 Clinical characteristics associated with 
poor retention have included mental health illness14,62, the year of their HIV diagnosis, 
higher CD4+ cell counts17,28,55, absence of AIDS diagnosis at baseline17,35,40, and AIDS defining 
illnesses (ADI) at baseline35,50. These studies of clinical characteristics may seem 
contradictory, but intuitively, they reflect expected health care seeking behaviors.14 Patients 
who enter into care without any health problems initially may not make their appointments 
because they do not feel sick and feel that there is no need to seek care, but patients who are 
sick may not attend appointments because they feel too sick to attend an appointment.14,50 
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 Other characteristics that affect retention in care have been lack of social support35, 
stigma related to HIV status63, distrust of the health system64, hospitalizations65, and use of 
ancillary services.53,55 Patients may not attend their scheduled clinic visits because of 
conflicts with work, lack of transportation, family illnesses, and hospitalizations.14,65 In 
1999, Palacio et al. published a study involving HIV-infected women, and found that the 3 
most common reasons for missing appointments were forgetfulness, conflict with multiple 
appointments, or feeling too sick to attend.66 A study of newly diagnosed persons living with 
HIV/AIDS found that the negative stigma related to HIV was a major reason for patients not 
retaining in care or even initiating care.63 
  Finally, researchers have suggested factors that may be predictors of optimal 
retention. The use of ancillary support services, defined as any type of service that offers 
support to the individual (e.g. case management/social work, mental health, nutritional 
counseling, substance abuse treatment, legal services, housing, transportation, translation, 
HIV drug assistance programs, and child care),  have been shown to be predictors of optimal 
care.53-55,67-69 A study involving 2,647 patients receiving HIV primary care in Chicago, 
Illinois, found that patients with case management were 17% more likely to receive regular 
primary care compared to those without case management.54 Researchers have also 
attempted to show that individuals who initiate HIV clinical care with non-HIV related 
comorbidity (e.g. diabetes, hypertension, renal disease, etc.) are more likely to retain in 
care, but results have been inconclusive.22,70 
Retention in Care and HIV clinical Outcomes 
 Researchers have recently studied the effects retention in care has on HIV clinical 
outcomes and have shown that poor retention is associated with worse health outcomes 
compared to optimal retention.14,15,21,22,24,28,41 Individuals who are poorly retained in care 
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are less likely to obtain a VL suppression24,25,45,47,48, more likely to be hospitalized65, more 
likely to acquire an ADI27, and more likely to die27-29,47 compared to those individuals who 
have optimal retention. From a public health standpoint, poor retention has been shown to 
increase the risk of antiretroviral resistance, decrease immune function, increase health 
care costs associated with increases in hospitalizations and emergency room use, and 
increase risky sexual behavior.14,31 
 Reducing the VL and maintaining VL suppression has become a major priority in the 
management of HIV as this reduces the infectivity of the individual living with HIV, thereby 
reducing the risk of transmission to others.24,29,31  Individuals who do not maintain optimal 
retention in care have a difficult time obtaining suppressed VLs and those who do acquire a 
VL suppression are more likely to rebound to VL failure.24 Mugavero et al. introduced a 
novel approach to observing VL over time; viremia copy-years, which is defined as the 
number of copies of HIV-1 RNA per ml per year circulating in plasma and integrated over 
the number of years from sero-conversion.24,71  The authors hypothesized that early optimal 
retention in care predicts shorter time to VL suppression and lower cumulative VL burden. 
The authors were interested in how retention in care affected time to suppression of plasma 
HIV RNA <50 copies per milliliter and cumulative VL burden (viremia copy-years), a time-
varying measure. In this study, the 676 individuals diagnosed with HIV between 2007 and 
2010 were recruited and followed for 2 years to observe time to VL suppression and 
cumulative VL. For the time to VL suppression analyses, the authors measured early 
retention in care as a time-varying count of “no show” visits, and for the evaluation of 2-
year viremia copy-years, the authors employed visit adherence, the proportion of scheduled 
visits that were attended.  
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The authors categorized visit adherence into three groups: 1)0% – 79%, 2) 80% – 
99%, and 3) 100%. Twenty-five percent of the individuals had 2 or more “no show” visits, 
and 63% achieved VL suppression in a median of 308 days from entry in to care. In the Cox 
proportional hazards analysis, individuals with multiple “no show” clinic visits experienced 
significantly longer time to VL suppression (Hazard Ratio: 0.84; 95% Confidence Interval = 
0.76 to 0.92).  In multivariable linear regression, visit adherence was independently 
associated with a lower cumulative VL burden.24 
Clinicians and researchers have focused most of their attention on the relationship 
between poor retention and VL suppression. There is a paucity of research on the 
relationship between retention and viral load rebound as well as the clinical progression of 
HIV disease. In 2007, Park et al. published an observational study where they observed the 
effect missed clinic visits had on clinical HIV progression.  From January 1998 to December 
2004, the authors included 387 individuals infected with HIV and seeking care in a tertiary 
referral hospital in Seoul, South Korea in the study and followed them for at least 1 year 
after the initiation of HAART. The authors defined retention in care as the number of missed 
clinic appointments and as the total cumulative number of days elapsed between a missed 
clinic visit and the next clinic visit summed over the follow-up period. Employing Cox 
proportional hazard models, the authors analyzed the relationship between missed clinic 
visits and the occurrence of new ADIs or death. Of the 387 individuals recruited for the 
analysis, 34% and 8% missed one or two appointments or three or more appointments 
respectively. New ADIs occurred in only 10% of the sample while a total of 8 died in the 
period of follow-up. Park et al. demonstrated that as the number of missed clinic visits and 
cumulative elapsed time increased, the hazard of progressing to a new ADI or death was 
1.54 and 1.23, respectively. Although the sample size was small and the follow-up time was 
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short, the authors were able to show how missing scheduled appointments can dramatically 
affect the clinical management of HIV, causing the acquisition of new ADIs and death.27 
Giordano employed a much larger medical chart review study (n= 2,619) to assess 
the relationship among visit constancy, a change in CD4+ cell counts, a change in VL, and 
survival. The authors restricted their study to only men living with HIV who were listed in 
the VA Immunology Case Registry. The follow-up for the analyses began a year after the 
index visit and ended at death or the end of the study period. The authors categorized the 
patients by the number of 3 month intervals in the year in which they had a primary care 
visit after their initial visit. A dose response relationship was found for visit constancy, 
significantly affecting CD4+ cell count, VL, and survival. The published study was significant 
as the researchers suggested that patients living with HIV should seek care at least once 
every three months as opposed to previous guidelines suggesting every 6 months.22 
Researchers have suggested that optimal retention may reduce HIV transmission, 
which carries a significant public health benefit.31 Metsch et al., in a longitudinal study 
showed that patients who had received HIV primary medical care at least 3 times in the 
preceding 6 months were significantly less likely to engage in unprotected vaginal or anal 
intercourse with HIV uninfected or unknown status partners in the preceding month.31 This 
finding is extremely important as retention in care can be used as a prevention method to 
reduce the incidence of HIV as approximately 56,000 new HIV cases are identified each year 
in the U.S.11,72 
Conclusion: Where are we now and what this dissertation proposes to add?  
 Retention in HIV medical care has become a significant topic among individuals 
living with HIV and deserves serious attention by both providers and public health agencies. 
It has been consistently shown by researchers, that patients in regular care are much more 
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likely to have better health outcomes, including VL suppression, than patients not in regular 
care. It is pertinent, at a programmatic and policy level, to identify and understand the 
factors beyond demographic characteristics that are related to poor retention in care, 
followed by an assessment of factors that can be addressed.14 If poor retention is truly the 
most basic predictor of health outcomes, it is pertinent for resources and funds to be set 
aside for interventions devoted to preventing poor retention.14 
 Retention in care studies are fairly easy to employ as these studies may rely heavily 
on medical chart reviewing and no physical interaction with subjects and this advantage 
allows retention in care studies to be relatively inexpensive.15 The way retention in care is 
measured varies and often depends on the data available to the researchers and clinicians 
as well as the reason for measuring retention. A major disadvantage with retention in care 
studies is the definition of retention. Unfortunately, there is no gold standard when it comes 
to defining retention in care, which makes comparison of studies difficult. To our 
knowledge, studies where a rigorous study has been conducted comparing multiple 
retention methods is rare.43 This may in part be because of the complex nature involving 
longitudinal follow-up.  
 There is a strong need for more longitudinal studies which assess how retention 
changes over time and how sporadic to poor retainers are re-engaged into care. Although 
predictors of poor retention have been established in most studies, future studies should 
continue to observe factors outside the normal socio-demographic characteristics, as there 
still may be factors that play a role in optimal or poor retention, and also understanding 
how retention over time impacts the disease progression.  
It is important to have consistent measurements of retention, but this will require 
making decisions on whether to focus on missed appointments or the number of completed 
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visits within a specified time period in order to capture retention in care.14 It is also 
important for researchers to consistently define a completed clinic visit; whether it includes 
only HIV primary care visits or all types of medical visits. This consistency will assist in the 
comparison of multiple studies. 
 The dissertation plans to tackle some of the issues described in the retention in HIV 
medical care literature as well as add important findings to the current literature. Since 
defining retention in care varies among studies and there is currently no study that has 
analytically compared multiple retention methods, the dissertation plans to compare 
multiple methods to determine the most appropriate method in defining retention, by 
determining their ability to predict viral suppression. The dissertation also hopes to add 
more predictors of poor to optimal retention to the current literature. It is inconclusive how 
non-HIV related comorbidities impact retention over time. Lastly, the dissertation plans to 
observe how poor retention over time impacts time to VL suppression and rebound. There 
are currently no studies that have observed the impact of poor retention on viral rebound 
among individuals who have achieved viral suppression. 
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Chapter Three 
A Comparison Study of Methods for Measuring Retention in HIV Medical Care 
Introduction 
 Retention in medical care among individuals living with HIV has become a major 
priority among HIV medical providers and public health researchers. Engagement in 
medical care is an important concept as it involves the process of an early diagnosis, linkage 
to care, initiation of antiretroviral therapy, and retention in HIV medical care.11,12,15 It is 
critical for individuals living with HIV, who are linked to care, to maintain optimal retention 
as this maximizes viral suppression, reduces the risk of AIDS progression, and reduces the 
risk of HIV transmission.22,24,27,31 According to the HIV Medicine Association guidelines, an 
enormous emphasis should be placed on retention to HIV medical care rather than just 
concentrating on adherence to HIV medications.73 
 Despite the importance of retention in HIV medical care, there has been limited 
research on this topic. Similar to adherence to HIV medication studies, the central concern 
for researchers and medical providers is how to best define retention.15,74,75 Measuring 
retention in HIV medical care can be complex as the process includes multiple clinic visits 
which occur longitudinally over time.15  Although multiple methods have been used in 
defining retention in HIV medical care, there is currently no standard preferred method. 
Researchers have suggested up to five different methods, each with their limitations on how 
to best measure retention in care.14,15 A consistent definition of retention must be set in 
place in order to compare results across studies. 
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 In spite of multiple researchers studying retention in care, rigorous study 
comparing different retention measurement techniques in order to determine the best 
method remains rare. Measurement of long-term retention can be complex as it requires a 
longitudinal assessment.15 To date, most studies have only employed one measure of 
retention and have focused on short time periods (1-3 years).13,16,21,22,28,38,39,43 Yehia et al 
recently published a study comparing three different retention measures, but focused on 
how each measure was correlated with one another. Understanding how each retention 
measure determines immunological and virological outcomes is essential as estimates show 
that approximately 20% of people living with HIV/AIDS (PLWHA) achieve viral load (VL) 
suppression and that this low percentage is largely due to poor retention.11,12  
Modeling adherence to HIV medication studies, methods are validated and chosen 
based on their ability to predict virological outcomes.74-76 To date, there has not been any 
study to observe multiple methods of retention to compare their ability to predict 
virological and immunological outcomes. The current study adds to the current research by 
comparing multiple measures of retention to HIV medical care. Using VL and CD4+ cell 
counts as the clinical criterion, the purpose of this study is to determine each measure’s 
ability to determine VL suppression and CD4+ cell count failure among PLWHA seeking HIV 
medical care at an academic infectious disease clinic.   
Methods 
Study Design 
 The purpose of this study was to determine retention in HIV medical care using 
three measurement techniques, and to compare their ability to predict VL suppression and 
CD4+ cell count failure. In order to accomplish this objective, a retrospective cohort study 
employing a medical chart review was conducted at an academic infectious disease clinic in 
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Kentucky (KY). Individuals who sought care between January 1st, 2003 and May 1st 2011 
were considered eligible for this study, and were followed until December 31st, 2011. 
January 1st, 2003 was chosen as the start date, since the care clinic integrated an electronic 
database during this time period, and May 1st, 2011 was chosen to be the recruitment end 
date, as this would allow individuals to have had at least six months of follow-up time at the 
end of the study period (allowing an individual to have a follow-up viral load and CD4+ cell 
count measurement). During the follow-up period, individuals were followed until the end 
of the study period (December 31st, 2011), death, or move out of service region. The study 
was approved by the University of KY Institutional Review Board. 
Study Site 
Individuals diagnosed with HIV and referred to the Bluegrass Care Clinic 
(BCC) for medical care were considered for inclusion in the study. The BCC is a 
multi-disciplinary HIV care clinic located in an urban area in KY.  The BCC is the 
largest of four HIV care providers in a 63 county area in KY federally funded through 
the Ryan White HIV/AIDS Treatment and Modernization Act of 2006, and non-
federal funds through the Commonwealth of KY. The BCC provides expert medical 
care by physicians, nurses, pharmacists, and other clinicians trained to deal with the 
complex management of a variety of infectious diseases, including HIV and related 
conditions. The BCC is home to approximately 1,050 active patients, which includes 
those living with HIV disease and approximately 50% of the patient population lives 
in rural areas in KY. 
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Study Population and Eligibility 
 Data for this study were abstracted from the HIV Lab Tracker TM, an electronic 
database located at the BCC. The HIV Lab Tracker TM is an advanced electronic database 
solution for managing patients living with HIV. The lab tracker encompasses a 
comprehensive list of information for each patient, which includes demographic, laboratory, 
medication, and clinical data.  
Individuals were considered for the study if they were diagnosed with HIV before or 
during the study period and were 18 years of age or older. To obtain the individuals that 
met the initial criteria, individuals were queried in the database on the following criteria: 1) 
HIV diagnosis date (May 1st, 2011 and earlier) and 2) Age (≥ 18 years). The query resulted 
in 1,485 individuals who were pulled from the database and were initially eligible for the 
research study. Individuals were included in the study if they sought HIV medical care at the 
BCC during the specified time period, had at least two completed clinic visits (intake visit 
and subsequent clinic visit), had at least 6 months of follow-up time, and had the 
appropriate dates recorded (clinic visits, HIV diagnosis, AIDS diagnosis, VL and CD4+ cell 
count dates). Of the 1,485 individuals pulled from the database, 1,358 individuals were 
included for follow-up (Figure 3.1).  
 The individuals included in the study were followed at 6 month intervals from their 
initial start date to the end of the follow-up period. Individuals, whose initial start date came 
before the beginning of the study period (January 1st 2003), were followed from their first 
completed clinic visit in the time frame.  
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 During each 6 month follow-up interval, the following information was observed: 
the number of completed clinic visits, laboratory results (i.e. VL and CD4+ cell counts), 
acquisition of new infections/diseases (e.g. AIDS, opportunistic infections, non-HIV related 
comorbidities), number of hospitalizations, and/or death. 
Baseline demographic and clinical data were abstracted from the HIV Lab Tracker TM 
database for those individuals that were included in the study. Demographic information 
included date of birth, sex, race/ethnicity, marital status, country of origin (U.S. 
born/Foreign born), employment status, insurance status (private, Medicare, Medicaid, and 
none), federal poverty level, history of tobacco use (yes/no), history of alcohol use (yes/no), 
history of illicit drug use (yes/no), and HIV transmission category (Men who have Sex with 
Men (MSM), Heterosexual contact, Injection Drug Users (IDU), and other). For the 
transmission category, ‘other’ consisted of transfusion, hemophilia, and unknown. Poverty 
level was defined using the federal poverty level guidelines and was dichotomized into 
<100% below the federal poverty level (income <$10,000) and >100% below the federal 
poverty level. Income was not complete for most patients, so poverty level was ascertained 
from the income values that were present for patients as well as the programs patients 
were enrolled in as these are based on their poverty level. For descriptive purposes, 
race/ethnicity was defined as Non-Hispanic (NH) White, NH Black, Hispanic, and other. Due 
to the small numbers of the non-white group, race was dichotomized into NH white versus 
non-white for the bivariate and multivariate analyses.  
Baseline clinical characteristics ascertained from the medical records included CD4+ 
cell counts (cells/µl), VLs (copies/ml), OI diagnoses, AIDS diagnoses, sexually transmitted 
infections, comorbidities, any hospitalizations, and receipt of HAART.  An individual was 
diagnosed with AIDS if they had one of the following:  a CD4+ cell count <200, a CD4+ cell 
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count percentage < 14, or one of the 26 AIDS defining Illnesses (ADIs).77  A concurrent AIDS 
diagnosis was defined as an AIDS diagnosis within 30 days of an HIV diagnosis. VL had a 
wide variation in its distribution and was greatly skewed, therefore, VL was log transformed 
and observed as log copies/ml for descriptive purposes.  Patients that initiated care with an 
AIDS diagnosis and had a missing CD4+ cell count result was given a value of 150 and a 
value of 250 if they had a missing CD4+ cell count and initiated care without an AIDS 
diagnosis. Death was ascertained using the social security death index and the EMR. For 
patients that were lost to follow-up or moved out of the service region, the social security 
death index assisted in determining the date of death for those patients, if necessary.  
Retention Measures 
 The current guidelines set by the U.S. Department of Health and Human Services 
(DHHS) for adolescents and adults with HIV states that primary care visits should be made 
by newly diagnosed persons at least every 3 to 4 months until initial patient evaluation is 
completed and stable clinical and immunological status is achieved for 2 to 3 years. 
Thereafter, at least one visit every six months is recommended for monitoring health 
outcomes.23 To determine the best method in defining retention in care, three measures of 
retention were observed during this study: 1) visit constancy; 2) gaps in care; and 3) the 
HRSA performance measure. Visit constancy was observed as the proportion (%) of 6-
month intervals with at least one clinic visit during the study period that the patient was a 
member of the cohort. Patients were classified into 4 groups: Optimal (100%), Suboptimal 
(99-75%), Sporadic (74-50%), and Poor (<50%).21 Gaps in care were defined as the time (in 
months) between two consecutive clinic visits. Patients were classified as ever having a gap 
<12 months or ≥ 12 months. The last retention measure involved a measurement described 
and used by HRSA and included in the National HIV/AIDS Strategy (NHAS).59 The HRSA 
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performance measurement was defined as having completed at least 2 clinic visits 
separated by 3 or more months within a 12-month period. To calculate this measure, each 
patient had their follow-up broken into 12-month intervals. For each interval, the HRSA 
performance measure was observed, and the proportion of 12-month intervals where the 
HRSA performance measurement criteria was met was calculated.58  A clinic visit was 
defined as an HIV medical outpatient care visit. Since laboratory tests were ordered by the 
HIV care physicians during each clinic visit, VL and CD4+ cell count measurements were 
used as surrogate clinic visits.  
Outcome Measures 
 At the end of the follow-up period, each individual’s final VL and CD4+ cell count was 
assessed. If an individual failed to acquire a VL or CD4+ cell count at the last 6 month 
interval, the measurement closest to the end of the study period was chosen. VL is the 
standard measurement for HIV treatment success or failure and is a surrogate measure for 
medication adherence, so the primary outcome was to understand how well retention 
discerns between those individuals who have a suppressed VL and those who do not. VL 
suppression was defined as achieving a VL of <50 copies/ml.24,78 The secondary outcome 
was CD4+ cell count failure and was defined as a 10% decrease in counts from baseline.79  
Statistical Analyses 
 Data were analyzed using the Statistical Analysis Software SAS version 9.3.; SAS 
Institute; Cary North Carolina. Descriptive statistics were employed for the entire study 
sample. Means and standard deviations were calculated to describe the continuous 
variables and frequencies and percentages were used to describe the categorical variables. 
For the bivariate and multivariate analyses, the sample was restricted to those individuals 
who had a follow-up VL and/or CD4+ cell count (Figure 3.1). Bivariate analyses observed 
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differences between groups and VL suppression and CD4+ cell count failure. To determine 
differences in means between those with and without VL suppression, independent two-
sample t tests were used. χ2 tests of independence were used to determine significant 
differences between categorical variables and VL suppression.  
 To determine the retention measure that most accurately predicted virological and 
immunological outcomes, receiver operating characteristic curves (ROC) were produced. An 
ROC curve is a plot of sensitivity as function of (1-specificity) for all possible cutoffs.80,81 
Logistic regressions were employed to obtain the ROC curves for visit constancy, gaps in 
care, and the HRSA performance measure. The purpose was to determine which 
measurement most accurately discriminated between those individuals who suppressed 
their VL and those who did not. The same steps were performed for discerning between 
those with a CD4+ cell count failure or not.  The area under the curve (AUC) estimates was 
produced with each ROC curve, and the AUC measure was used to determine the ability of 
each retention measure to correctly classify those individuals with a suppressed VL and 
those without a suppressed VL and the same for cell count failure.80 Separately, each 
retention measure’s AUC was compared to chance (AUC = 0.5), and χ2 tests were used to 
determine whether the retention measure’s AUC was significantly different from chance. An 
AUC that was significantly greater than chance was considered a useful measure in correctly 
discerning between the different groups. Each retention measure was then compared to 
each other to determine the best measure in predicting the outcomes.   
 Multiple logistic regression models were performed for each retention measure 
(visit constancy, gaps in care, and HRSA) to determine the relationship between each 
retention measure and the virological and immunological outcomes while controlling for 
confounders and other risk factors. Variables with a p-value ≤0.15 in the bivariate analyses 
 
32 
 
were considered for inclusion into each regression model. Variables were included in the 
model as confounders based on previous literature. Variables that were initially included in 
the models that did not appear to have an effect on the outcome or confound the 
relationship between retention and the outcome were removed from the model. 
Interactions between each variable and the retention measure were tested. There was a 
significant interaction between initial CD4+ cell count and initial VL. The Hosmer and 
Lemeshow goodness of fit tests were used to determine each models fit and Akaike 
Information Criteria (AIC) was used to determine which fitted model was best. 
 The multiple logistic regression, modeling the probability of not obtaining VL 
suppression, included race, insurance type, initial CD4+ cell counts and VLs interaction, 
concurrent HIV/AIDS diagnosis, year of HIV diagnosis, and HAART. The logistic regression, 
modeling the probability of CD4+ cell count failure, included race, insurance type, initial 
CD4+ cell counts and VLs, concurrent HIV/AIDS diagnosis, year of HIV diagnosis, and 
HAART.   
Results 
Demographic and Clinical Characteristics 
Of the 1,358 individuals included in the analysis, the mean age at the start of the 
study period was 38 ± 10 years, 81.2% (n = 1,102) were male, and 70.2% (n= 952) were 
Non-Hispanic White (Table 3.1). A large proportion of the population entered clinic care 
living below the poverty level (48.9%), with approximately 42.6% (n= 569) having no 
insurance (Table 3.1).   
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 Over half of the population acquired an AIDS diagnosis (53.3%) throughout the 
study period, with 25.1% of them having a concurrent diagnosis. Approximately 28.3% of 
the individuals initiated care with a CD4+ cell count <200 cells/µl meaning that these 
individuals entered the study at a much advanced stage of disease.  A total of 1,166 (85.9%) 
patients had initiated HAART (Table 3.1). 
 Among the 1,358 patients included in the study, the mean years of follow-up were 
5.75 ± 2.65 years (median = 6.20) and the patients completed a mean of 39.6 ± 39.8 clinic 
visits (median = 28.0). At the end of the follow-up period, 797 (59%) patients had a follow-
up VL recorded, but only 57.8% of those achieved a suppressed VL. Non-whites, individuals 
living below the poverty level, those uninsured or on Medicaid, non-concurrent diagnosed 
individuals, and those with CD4+ cell counts <200 cells/μL were less likely to achieve a 
suppressed VL compared to their counterparts (Table 3.2). 
 For CD4+ cell count failure, 824 (61%) patients that a follow-up measurement 
recorded during the study period, and approximately 26% of the patients had an 
immunological failure. Patients with Medicaid or no insurance were more likely to have a 
failure compared to those with Medicare and private insurance. Immunological failure was 
also more likely to be found in those patients without a concurrent diagnosis, without 
HAART, and those with higher CD4+ cell counts and VLs at initiation (Table 3.2). 
Retention in Care Measures 
 Table 3.3 presents the retention in care measurements. Overall the average 
percentage of 6-month intervals with at least one visit (visit constancy) was 77.6 ±29.9% 
(median = 94.1), with 48.6% having at least one visit every six months (optimal retention) 
over the 9-year study period.  For the HRSA performance measurement, the average 
percentage of 12-month intervals where the criteria was met was 77.2 ±29.7% (median = 
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88.9) among the entire study sample. However, only 592 (43.6%) patients met the HRSA 
criteria every 12-month period they were in the study. The longest time between 
consecutive visits was collected for each patient in the study. The average time between two 
consecutive visits for the sample was 8 ±9.1 months (median = 5.5). Throughout the study 
period, 15.5% of the patients had at least one interval greater than 12 months.   
VL suppression was more likely among those patients who met each retention 
criteria (Table 3.3). For the HRSA performance measure, the mean percentage of intervals 
with at least two visits separated by 3 or more months was higher for those with a 
suppressed VL compared to those without a suppressed VL (88.8% versus 78.0%, 
p<0.0001). Approximately 61% of the individuals who met the HRSA criteria 100% percent 
of the time had a suppressed VL compared to just 55.6% of those who did not meet the 
criteria. Patients who had an interval greater than 12 months were less likely to achieve a 
suppressed VL compared to those with intervals less than 12 months (43.3% versus 61.0%, 
p = 0.0001). On average, patients with a suppressed VL had more 6-month intervals with at 
least one visit compared to those who did not have a suppressed VL (93.5% versus 69.9%, p 
<0.0001). Dividing visit constancy into categories, there was a clear dose response for 
individuals achieving a suppressed VL. Approximately 74% of optimal retainers achieved a 
suppressed VL compared to 58%, 36.9%, and 5.4% for suboptimal, sporadic, and poor 
retainers, respectively (p<0.0001). 
 CD4+ cell count failure was more likely among those patients that did not retain 
fully in care. The mean percentage of 12-month intervals where the HRSA criteria was met 
was lower for those with a failure compared to those without a failure (79.1% versus 
84.9%, p = 0.001). The average time between two consecutive visits was higher for those 
with a CD4+ cell count failure compared to those without a count failure (11.4 versus 8.4 
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months, p = 0.001).  On average, patients with a CD4+ cell count failure had less 6-month 
intervals with at least one visit compared to those who did not have a failure (79.1% versus 
85.0%, p = 0.004) (Table 3.3). 
 Tables 3.4 and 3.5 present the ROC statistics for predicting VL suppression and 
CD4+ cell count failure, respectively. For VL suppression, the AUCs were larger for visit 
constancy (0.736) than for the HRSA performance measure (0.603), and gaps in care 
(0.532). Compared to chance (AUC = 0.5), gaps in care was the only retention measure that 
was not significantly greater than chance (p=0.133), suggesting that gaps in care is not a 
good measure in discerning between VL suppressers and non-suppressers (Table 3.4). 
Figure 3.1 presents the ROC curves for the retention measures, and it shows that visit 
constancy outperforms gaps in care and the HRSA performance measure (p<0.0001). For 
determining CD4+ cell count failure, the three retention measures did not perform well in 
determining those patients with cell count failure (Figure 3.2). There were no differences in 
the AUCs among the three retention measures, although each measure was significantly 
different from chance (Table 3.5).   
 Multiple logistic regressions were performed to determine the association of each 
retention measure with viral suppression and CD4+ cell count failure, while controlling for 
the confounding variables. While controlling for the variables, gaps in care and visit 
constancy were significantly associated with viral suppression (Table 3.6). Patients with 
gaps >12 months had greater odds of not achieving viral suppression compared to those 
with gaps <12 months (Odds Ratio (OR) = 1.88; 95% Confidence Interval (CI) = 1.26, 2.80). 
Compared to optimal retainers, suboptimal (OR = 2.09; 95% CI = 1.44, 9.41), sporadic (OR = 
5.50; 95% CI = 3.20, 9.41), and poor retainers (OR = 44.2; 95% CI = 17.0, 114.6) were at 
greater odds of not suppressing VLs (Table 3.6). There were no significant interactions 
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between the variables and retention, but there was a significant interaction between initial 
VL and CD4+ cell counts, suggesting that lower CD4+ cell counts and higher VLs were at 
greater odds of failing to have viral suppression (data not shown). While controlling for the 
confounding variables, the HRSA performance measure, gaps in care, and visit constancy 
were all significantly associated with CD4+ cell count failure (Table 3.7).  Patients that did 
not meet the HRSA performance criteria were 1.53 times the odds of failure compared to 
those where the criteria was met. Compared to optimal retainers, sporadic and poor 
retainers had greater odds of cell count failure at 1.85 and 1.84, respectively.  
Discussion 
A major issue with retention in care studies is determining how to best define 
retention in HIV outpatient medical care among PLWHA. It has been suggested that there 
are at least five different ways to measure retention and currently no gold standard is in 
place, which makes comparison of studies difficult.14,15 There is still a debate on which 
retention measure to use. The purpose of this study was to compare three different 
measures of retention by determining their ability to predict VL suppression and CD4+ cell 
count failure. For VL suppression, it was found that visit constancy outperformed the HRSA 
performance measure and gaps in care in regards to discerning between those patients with 
and without VL suppression. For CD4+ cell count failure, it was found that all three 
retention measures performed poorly when determining failure. 
The means for HRSA measure and visit constancy were similar among the study 
sample, with approximately 77.2% of all 12-month patient-care intervals having met the 
HRSA criteria and approximately 77.6% of all 6-month patient-care intervals having at least 
one visit. For gaps in care, we were able to show that the longest average time between two 
consecutive visits was approximately 8 months. Our study is among the few studies to 
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employ a relatively long follow-up period to measure retention in care, with an average 
follow-up time of 5 years among the entire cohort.82,83 Yehia et al. in 2012 conducted a 
similar study, comparing the HRSA performance measure, visit constancy and gaps in care 
measures among a cohort of adults enrolled in an HIV Research Network (HIVRN). Using 3-
month intervals to estimate visit constancy and an average follow-up time of 35.5 months, 
73% of all 3-month intervals had at least one visit and 75% of all 12-month intervals met 
the HRSA measure.43 In our cohort, the mean percentages were slightly higher than the 
Yehia et al. cohort. Reasons for this could be the cohort chosen for the study (Ryan White 
population versus HIVRN network), the sample size (1358 versus 17,425), or the choice in 
patient-care intervals (6 months versus 3 months). 
In our study, approximately 44% of the cohort met the HRSA criteria 100% of the 
time. The HRSA performance measure is a measure created and endorsed by HRSA and 
described in NHAS. The measure was created to be used as an indicator for providers 
receiving Ryan White CARE Act funding and is typically restricted to just 12 months.15,58 We 
followed individuals over a 9 year period to calculate the percentage of years where the 
criteria were met. Until recently, the HRSA measurement was not observed in most 
retention studies38,39,43, but Hall et al. conducted a study using HIV surveillance data from 13 
areas in the U.S. and showed that approximately 45% of PLWHA had met the HRSA 
criteria.39 Our results were similar to theirs. 
Observing visit constancy among all the patients in the study, only 49% had optimal 
retention (all 6-month patient-care intervals had at least one clinic visit) while 
approximately 12% had poor retention (<50% retention). The retention rate among our 
study sample is rather low and falls below the goal set by NHAS to increase the proportion 
of clients who are in continuous care from 73% to 80%. In regards to gaps in care, only 
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15.5% of the cohort had one or more gaps >12 months, which is lower than what most 
studies have reported.43,51,84 The data strongly suggests that significant energy needs to be 
put toward increasing the number of individuals optimally retained in care and 
understanding the factors that may impact retention among this cohort is a key component. 
Further studies should be conducted and strategies should be set in place to re-engage 
those that are lost to follow-up.  
 The measures of retention to medical care calculated in this study were compared to 
one another by employing methods described in adherence to HIV medication studies.74-76 
Measures were compared based on their ability to predict VL suppression since VLs are 
normally used as surrogate measures for medication adherence and determining how well a 
patient is managing their disease.74,79 It was shown that visit constancy had the highest AUC 
compared to the other two measures, suggesting a higher chance of discerning VL 
suppression. In 2001, Liu et al conducted a similar study, but used ROC curves to determine 
the relationship between medication adherence and VL suppression. The average AUC 
calculated for the adherence measures was 77.5%.76 The AUC calculated for visit constancy 
in the current study was 73.6% which suggests that visit constancy may be potentially used 
as a surrogate measure for measuring adherence to medication for programs that do not 
have the resources to conduct medication adherence studies. Future studies should be 
conducted to determine the relationship between medication adherence and retention to 
medical care, in particular visit constancy. 
 Only 58% of the patient cohort had achieved VL suppression by the end of follow-
up, but of those approximately 74% were optimal retainers. The logistic regressions 
suggested that poor retention in care greatly hinders a patient from achieving a suppressed 
VL. While controlling for the confounding variables, gaps in care and visit constancy were 
 
39 
 
the only measures significantly associated with the failure to achieve VL suppression. 
Comparing AICs, visit constancy had the better fitted model suggesting it should be 
considered the best retention in care measure. With visit constancy, the individuals that 
were suboptimal, sporadic, and poor retainers had much greater odds of VL failure 
compared to optimal retainers. This is an interesting finding as there appears to be a dose-
response, suggesting that an individual needs to maintain 100% retention in order to 
achieve adequate VL suppression. The results have major implications on the health of the 
individual as well as public health prevention efforts. Individuals that are not retaining in 
care are missing opportunities to suppress their VLs which in turn puts them at risk for 
transmitting the virus to others.  
There are limitations to this study. The study was an observational, retrospective 
cohort study and subject to potential uncontrolled confounders that could not be identified 
and studied. Medical chart review was employed to capture the study information, but not 
all patients had complete information in their records. Patients with missing VL or CD4+ cell 
count information were excluded from the study. Excluding patients dues to missing 
information may introduce bias and reduce the power of the study. However, there were no 
significant differences in demographic and clinical characteristics between those that were 
excluded from the analysis. 
The percentage of patients missing VL and CD4+ cell counts in this study is a 
concern. The DHHS panel on antiretroviral guidelines for Adults and Adolescents 
recommends regular monitoring of disease status and treatment response with CD4+ cell 
counts and VLs every 3-4 months, but once VLs have been suppressed CD4+ cell counts may 
be measured less frequently (6-12 months).23 The majority of the patients in the study were 
on HAART, and a percentage of them did not have laboratory tests done. Retention in care 
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seems to play a role in this scenario, as even after individuals have reached viral 
suppression they should continue to visit the clinic and have lab work conducted to ensure 
they do not rebound to viral failure.   
Another limitation to this study was the definition for clinic visits. In the retention in 
care literature, it is debated as to what constitutes a clinic visit.14,15  For this study, a clinic 
visit was defined as an HIV medical care visit (outpatient) and laboratory results (i.e. VL or 
CD4+ cell counts) were considered surrogate measures. To be consistent with other studies, 
medical care visits with a non-HIV care provider were not included in the clinic visit 
definition. This limitation could lead to a misclassification bias as individuals who seek 
medical care from non-HIV providers may be classified as poor retainers, therefore 
overestimating non-retainers in the study. There is the potential for selection and 
misclassification bias as individuals were removed from the study when they did not have a 
follow-up visit after their initial visit or at least 6 months of follow-up. Removing these 
individuals from the analysis may underestimate the number of poor retainers seeking 
medical care at the BCC.  It was not feasible to find out if these individuals were seeking HIV 
medical care at other clinics. We do not believe patients would seek care at other clinics 
often because most of the patients relied on funding from the clinic for medication and 
patient care and other options for HIV/AIDS care in their region may be limited.  
Finally, medication adherence was not observed or evaluated in this study. Studies 
have observed the impact medication adherence has on viral suppression as well as viral 
rebound, and have suggested that patients that are not at least 95% adherent to their 
medications are more likely to have virological failures. Medication adherence is on the 
causal pathway between retention in care and VL suppression, but the purpose of this study 
was to establish the relationship between retention and VL suppression. It may be 
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concluded that medication adherence is the driving force behind viral suppression, but 
Giordano et al were able to show that poor retention in care and poor medication adherence 
were highly correlated therefore it seemed appropriate to use retention in care as a 
surrogate measure.85 Also obtaining medication adherence is difficult.  As with the patient 
population at the BCC, patients may obtain their medications from multiple pharmacies, 
making it difficult to track medication usage. If a centralized pharmacy were available for 
this population, medication adherence may have been accurately assessed.   
Conclusion 
 When defining retention to HIV medical care, our study indicated that visit 
constancy may be the most appropriate measure. Visit constancy outperformed HRSA and 
gaps in care predicting VL suppression and was significantly associated with CD4+ cell 
count failure. It was shown that approximately 42% of the patients in the study did not 
achieve viral suppression and 26.2% had a CD4+ cell count failure. Poor retention may have 
a role in the failure to maintain successful management of HIV as only 48.6% of the patient 
cohort was able to maintain optimal retention. Interventions should be set in place to 
increase the number of optimal retainers and re-engage those individuals that have 
completely fallen out of care. 
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Table 3.1 Socio-demographic and Clinical 
Characteristics among the Patients Seeking HIV 
Medical Care: 2003 - 2011 
  
Total                     
   n (%) 
Total 1358 (100) 
Sex 
 Female 256 (18.9) 
Male 1102 (81.2) 
Race 
 White Non-Hispanic 952 (70.2) 
Black Non-Hispanic 273 (20.1) 
Hispanic 123 (9.1) 
Other 8 (0.6) 
Age at Baseline 
 ≤24 yrs 136 (10.0) 
25 - 34 yrs 362 (26.7) 
35 - 44 yrs 504 (37.1) 
>44 yrs 356 (26.2) 
Age mean (std) 38.2 (10.05) 
Mode of Transmission 
 Heterosexual 385 (28.4) 
IDU 122 (9.0) 
Other 72 (5.3) 
MSM 777 (57.3) 
Employment Status 
 Employed 501 (44.8) 
Unemployed 402 (36.0) 
Other 215 (19.2) 
Poverty Level 
 Below Poverty Level 662 (48.8) 
Above Poverty Level 446 (32.8) 
Missing 250 (18.4) 
History of Tobacco Use 
 Yes 686 (50.5) 
No 672 (49.5) 
History of Illicit Drug 
Use 
 Yes 365 (26.9) 
No 993 (73.1) 
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Table 3.1 continued 
  Total 
Insurance Type 
 No Insurance 569 (42.6) 
Medicaid 212 (15.9) 
Medicare 211 (15.8) 
Private 344 (25.8) 
Concurrent 
Diagnosis 
 Concurrent 341 (25.1) 
Non-Concurrent 1017 (74.9) 
History of AIDS 
Diagnosis 
 Yes 724 (53.3) 
No 634 (46.7) 
History of 
Hospitalizations 
 Yes 738 (54.3) 
No 620 (45.7) 
Hepatitis C 
 Yes 172 (12.7) 
No 1186 (87.3) 
HAART Use 
 Yes 1166 (85.9) 
No 192 (14.1) 
CD4+ Cell Counts 
 <200 384 (28.3) 
>200 974 (71.7) 
Initial Viral Load 
mean log copies 
(std) 6.75 (3.05) 
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Table 3.2 Socio-demographic and Clinical Characteristics by Virological and 
Immunological Outcomes among the Patients Seeking HIV Medical Care: 2003 - 2011 
 
Suppressed Viral Load (n = 797) CD4 Failure (n = 824) 
  
Yes               
n (%) 
No                  
n (%) p 
Yes               
n (%) 
No                  
n (%) p 
Total 461 (57.8) 336 (42.2) 
 
216 (26.2) 608 (73.8) 
 Sex 
  
0.15 
  
0.43 
Female 79 (52.7) 71 (47.3) 
 
44 (28.8) 109 (71.2) 
 Male 382 (59.0) 265 (41.0) 
 
172 (25.6) 499 (74.4) 
 Race 
  
<0.0001 
  
0.26 
Non-White 84 (42.9) 112 (57.1) 
 
60 (29.3) 145 (70.7) 
 White 376 (62.7) 224 (37.3) 
 
156 (25.2) 462 (74.8) 
 Age at 
Baseline 
  
0.24 
  
0.54 
≤24 yrs 31 (54.4) 26 (45.6) 
 
18 (30.5) 41 (69.5) 
 25 - 34 yrs 101 (52.1) 93 (47.9) 
 
59 (28.9) 145 (71.1) 
 35 - 44 yrs 190 (60.1) 126 (39.9) 
 
83 (25.5) 242 (74.5) 
 >44 yrs 139 (60.4) 91 (39.6) 
 
56 (23.7) 180 (76.3) 
 Mode of 
Transmissio
n 
  
0.47 
  
0.15 
Heterosexual 131 (59.8) 88 (40.2) 
 
60 (26.3) 168 (73.7) 
 IDU 39 (50.0) 39 (50.0) 
 
28 (35.9) 50 (64.1) 
 Other 22 (55.0) 18 (45.0) 
 
12 (30.0) 28 (70.0) 
 MSM 269 (58.5) 191 (41.5) 
 
115 (24.1) 362 (75.9) 
 Employment 
Status 
  
0.01 
  
0.75 
Employed 203 (65.5) 107 (34.5) 
 
78 (24.5) 240 (75.5) 
 Unemployed 131 (53.9) 112 (46.1) 
 
69 (27.3) 184 (72.7) 
 Other 91 (65.5) 48 (34.5) 
 
36 (25.2) 107 (74.8) 
 Poverty 
Levela 
  
<0.0001 
  
0.08 
Below 
Poverty Level 207 (53.2) 182 (46.8) 
 
120 (29.6) 285 (70.4) 
 Above 
Poverty Level 203 (68.1) 95 (31.9) 
 
67 (22.2) 235 (77.8) 
 Missing 51 (46.4) 59 (53.6) 
 
29 (24.8) 88 (75.2) 
 History of 
Tobacco Use 
  
0.05 
  
0.6 
Yes 226 (54.6) 188 (45.4) 
 
116 (27.0) 314 (73.0) 
 No 235 (61.4) 148 (38.6) 
 
100 (25.4) 294 (74.6) 
 History of 
Illicit Drug 
Use 
  
0.10 
  
0.14 
Yes 103 (52.8) 92 (47.2) 
 
62 (30.1) 144 (69.9) 
 No 358 (59.5) 244 (40.5)   154 (24.9) 464 (75.1)   
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Table 3.2. Continued 
 
Viral Suppression CD4 Failure 
  
Yes               
n (%) 
No                  
n (%) p 
Yes               
n (%) 
No                  
n (%) p 
Insurance Type 
  
0.003 
  
0.03 
No Insurance 150 (52.6) 135 (47.4) 
 
86 (28.4) 217 (71.6) 
 Medicaid 68 (50.8) 66 (49.3) 
 
46 (33.6) 91 (66.4) 
 Medicare 94 (61.8) 58 (38.2) 
 
33 (21.2) 123 (78.9) 
 Private 149 (66.8) 74 (33.2) 
 
49 (21.8) 176 (78.2) 
 Concurrent 
Diagnosis 
  
0.04 
  
0.01 
Concurrent 129 (64.2) 72 (35.8) 
 
40 (19.3) 167 (80.7) 
 Non-Concurrent 332 (55.7) 264 (44.3) 
 
176 (28.5) 441 (71.5) 
 History of AIDS 
Diagnosis 
  
0.01 
  
0.23 
Yes 249 (54.0) 212 (46.0) 
 
133 (27.8) 346 (72.2) 
 No 212 (63.1) 124 (36.9) 
 
83 (24.1) 262 (75.9) 
 History of 
Hospitalizations 
  
0.10 
  
<0.001 
Yes 274 (55.6) 219 (44.4) 
 
161 (31.4) 352 (68.6) 
 No 187 (61.5) 117 (38.5) 
 
55 (17.7) 256 (82.3) 
 Hepatitis C 
  
0.19 
  
0.1 
Yes 54 (51.9) 50 (48.1) 
 
36 (32.7) 74 (67.3) 
 No 407 (58.7) 286 (41.3) 
 
180 (25.2) 534 (74.8) 
 HAART Use 
  
<0.001 
  
<0.001 
Yes 449 (60.3) 296 (39.7) 
 
185 (24.5) 571 (75.5) 
 No 12 (23.1) 40 (76.9) 
 
31 (45.6) 37 (54.4) 
 CD4+ Cell 
Counts 
  
0.001 
  
0.006 
<200 98 (48.3) 105 (51.7) 
 
40(19.1) 170 (80.9) 
 >200 363 (61.1) 231 (38.9) 
 
176 (28.7) 438 (71.3) 
 Initial Viral 
Load mean log 
copies (std) 6.16 (3.01) 6.94 (3.01) <0.001 
6.72 
(2.90) 6.45 (3.07) <0.001 
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Table 3.3. Retention in Care Measures by Immunological and Virological Outcomes among the Patients Seeking HIV 
Medical Care: 2003 - 2011 
 
Total 
(n=1358)   Viral Suppression (n=797) CD4+ Cell Count Failure (n=824) 
  n (%) 
Yes                   
n (%) 
No                  
n (%) p-value 
Yes                   
n (%) 
No                  
n (%) p-value 
HRSA  
       Mean %(std) 77.2 (29.7) 88.8 (14.6) 78.0 (25.8) <0.0001 79.1 (23.4) 84.9 (21.0) 0.001 
Yes 592 (43.6) 217 (60.6) 141 (39.4) 0.15 81 (22.1) 286 (77.9) 0.02 
No 766 (56.4) 244 (55.6) 195 (44.4) 
 
135 (29.5) 322 (70.5) 
 Gaps in Care 
       Mean months (std) 8.1 (9.1) 7.9 (6.1) 10.6 (11.9) 0.12 11.4 (12.4) 8.4 (8.4) 0.001 
>12 months 210 (15.5) 61 (43.3) 80 (56.7) 0.0001 60 (40.8) 87 (59.2) <0.0001 
<12 months 1148 (84.5) 400 (61.0) 256 (39.0) 
 
156 (23.0) 521 (77.0) 
 Visit Constancy 
       Mean %(std) 77.6 (29.9) 93.5 (11.9) 69.9 (30.3) <0.0001 79.1 (23.4) 85.0 (23.6) 0.004 
Optimal 660 (48.6) 301 (73.8) 107 (26.2) <0.0001 90 (21.2) 334 (78.8) 0.002 
Suboptimal 281 (20.7) 124 (58.2) 89 (41.8) 
 
67 (31.0) 149 (69.0) 
 Sporadic 158 (11.6) 31 (36.9) 53 (63.1) 
 
22 (25.6) 64 (74.4) 
 Poor 259 (19.1) 5 (5.4) 87 (94.6)   37 (37.8) 61 (62.2)   
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Table 3.4. Receiver Operating Characteristic Curve Statistics for Detecting Viral Suppression 
Variable 
Area Under 
the Curve 
(AUC) 
Standard Error 
95% CI 
p-value Lower  Upper 
Bound Bound 
Visit Constancy 0.736 0.017 0.702 0.77 <0.0001 
HRSA Performance 0.603 0.02 0.563 0.642 <0.0001 
Gap in Care 0.532 0.021 0.49 0.574 0.133 
Note: p-values denote differences between each retention measure and chance using chi-square tests 
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Table 3.5. Receiver Operating Characteristic Curve Statistics for Detecting CD4+ Cell Count Failure 
Variable 
Area Under 
the Curve 
(AUC) 
Standard Error 
95% CI 
p-value Lower  Upper 
Bound Bound 
Visit Constancy 0.573 0.022 0.531 0.615 0.001 
HRSA Performance 0.577 0.022 0.533 0.620 0.001 
Gap in Care 0.572 0.024 0.525 0.618 0.003 
Note: p-values denote differences between each retention measure and chance using chi-square tests 
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Table 3.6. Multiple Logistic Regression of Viral Suppression by Retention in Care Categories 
 
Viral Load Failure 
  
Yes                 
n (%) 
No                 
n (%) OR 95% CI aOR 95% CI 
HRSA HAB 
      Yes 141 (39.4) 217 (60.6) Ref 
 
Ref 
 No 195 (44.4) 244 (55.6) 1.23 (0.93, 1.63) 1.25 (0.92, 1.69) 
Gaps in Care 
      >12 months 80 (56.7) 61  (43.3) 2.05 (1.42, 2.96) 1.88 (1.26, 2.80) 
<12 months 256 (39.0) 400 (61.0) Ref 
 
Ref 
 Visit 
Constancy 
      Optimal 107 (26.2) 301 (73.8) Ref 
 
Ref 
 Suboptimal 89 (41.8) 124 (58.2) 2.02 (1.42, 2.87) 2.09 (1.44, 3.04) 
Sporadic 53 (63.1) 31 (36.9) 4.81 (2.93, 7.89) 5.5 (3.2, 9.41) 
Poor 87 (94.6) 5 (5.4) 48.91 (19.34, 123.6) 44.2 (17.0, 114.6) 
 
 
 
 
 
5
0
 
Table 3.7. Multiple Logistic Regression of CD4+ Cell Count Failure by Retention in Care Categories 
 
CD4+ Cell Count Failure 
  
Yes                 
 n (%) 
No                
  n (%) OR 95% CI aOR 95% CI 
HRSA HAB 
      Yes 81 (22.1) 286 (77.9) Ref 
 
Ref 
 No 135 (29.5) 322 (70.5) 1.48 (1.08, 2.04) 1.53 (1.09, 2.15) 
Gaps in Care 
      >12 months 60 (40.8) 87 (59.2) 2.30 (1.58, 3.35) 2.04 (1.37, 3.06) 
<12 months 156 (23.0) 521 (77.0) Ref 
 
Ref 
 Visit 
Constancy 
      Optimal 90 (21.2) 334 (78.8) Ref 
 
Ref 
 Suboptimal 67 (31.0) 149 (69.0) 1.67 (1.15, 2.42) 1.85 (1.24, 2.75) 
Sporadic 22 (25.6) 64 (74.4) 1.28 (0.75, 2.18) 1.3 (0.73, 2.32) 
Poor 37 (37.8) 61 (62.2) 2.25 (1.41, 3.60) 1.84 (1.08, 3.12) 
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Figure 3.1 Flow chart of the Patients Enrolled in the Study 
  
1485 patients 
abstracted from the 
Lab Tracker 
Database 
1478 patients 
sought care at the 
BCC between 
January 1st, 2003 
and May 5th, 2011 
120 patients were 
ineligible for 
inclusion in the 
study 
1358 patients met 
the inclusion 
criteria for the 
initial study 
797 patients had a 
follow-up viral load 
measurement  
824 patients had a 
follow-up CD4+ cell 
count 
measurement 
3 patients were 
removed due to 
duplicate charts 
4 patients were 
removed due to 
inaccurate or 
unknown HIV 
diagnosis dates 
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Figure 3.2 Receiver Operating Characteristic Curves Detecting Viral 
Suppression 
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Figure 3.3 Receiver Operating Characteristic Curves Detecting CD4+ 
Cell Count Failure 
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Chapter Four 
Impact of non-HIV Related Comorbidities on Retention in HIV Medical Care: Does Retention 
Improve over Time 
Introduction 
 Despite the major advances and benefits of HIV medical care (i.e. HAART) and a 
publicly funded system which provides HIV medical care to those who otherwise would not 
seek care (Ryan White Modernization Act), a large portion of people living with HIV/AIDS 
(PLWHA) do not seek continuous medical care.12 Approximately 40-50% of PLWHA’s, who 
are aware of their HIV status, are not seeking optimal medical care, which can pose 
significant harms to the management of their HIV infection.11-13 According to the national 
HIV/AIDS strategy for the United States, the goal is to increase the proportion of newly 
diagnosed patients linked to clinical care within three months of their diagnosis from 65% 
to 85%, and to increase the percentage of those clients enrolled in the Ryan White 
HIV/AIDS Program who are optimally retained in medical care from 73% to 80%, by 
2015.59 
 It is imperative for PLWHA to maintain optimal care throughout the course of their 
infection, as PLWHA who are poorly retained in HIV medical care are less likely to receive 
the appropriate medications (e.g. HAART and Opportunistic Infections prophylaxis), are 
more likely to have poor medication adherence, and are more likely to acquire resistance to 
HAART.15,19,34,85 Also, poorly retained HIV infected patients have difficulties maintaining 
viral load suppression as well as maintaining high CD4+ cell counts.21,24,25,28,44,45,48 
Understanding the factors that impact retention to HIV medical care is important as 
researchers and clinicians feel that this should take priority over medication adherence.73 
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In recent years, researchers have established predictors of poor and optimal 
retention, but have focused solely on general socio-demographic factors (e.g. age, race, sex, 
and income) and how they predict poor retention for a specific time period.21,38,40,43,46,60 
Little is known about how retention changes over an extended time period and what factors 
may affect this change. For example, non-HIV related comorbidities like cancer, 
cardiovascular disease, respiratory disease, and mental health may have an impact on 
retention in medical care,22,62,86,87 for there has been an increase in the number of 
comorbidities diagnosed among PLWHA (e.g. approximately 50% of PLWHA have a mental 
illness and 13% have both a mental illness and substance abuse).59 Braithwaite et al 
conducted a mathematical model to show that the number of PLWHA with non-HIV related 
comorbidities will increase over time and that these conditions will probably be the cause 
of death in patients, not the underlying HIV infection.88 
Researchers studying comorbid conditions have specifically focused on the impact 
of mental health illnesses and substance abuse problems on retention to medical care and 
have very short follow-up periods.62,70,86 Giordano et al. observed PLWHA with a comorbid 
condition for two years, and showed that PLWHA with any type of comorbid condition were 
less likely to be poor retainers compared to those without a comorbid condition.22 As 
PLWHA age and continue the long-term use of HAART, the likelihood of having multiple 
comorbid conditions increases, and it is important to understand how the acquisitions of 
comorbid conditions affect retention over time.  
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The purpose of this study is to understand the predictors of less than optimal 
retention in HIV medical care and to understand how the presence of one or more comorbid 
conditions affects retention over time among a cohort seeking care at a Ryan White clinic in 
Kentucky. This study extends prior research by observing multiple comorbid conditions and 
incorporating a longer observational period (9 years). 
Methods 
Study Design 
 To determine the impact comorbid conditions have on HIV medical care retention, a 
retrospective cohort study employing a medical chart review was conducted at an academic 
infectious disease clinic at the University of Kentucky (KY). Patients who sought care 
between January 1st, 2003 and May 1st 2011 were considered eligible for this study, and 
were followed until December 31st, 2011. During the follow-up period, patients were 
followed until the end of the study period (December 31st, 2011), death, or move out of 
service region. The study was approved by the University of KY Institutional Review Board. 
Study Site 
Patients diagnosed with HIV and referred to the Bluegrass Care Clinic (BCC) 
for medical care were considered for inclusion in the study. The BCC is a multi-
disciplinary HIV care clinic located in an urban area in KY.  The BCC is the largest of 
four HIV care providers in a 63 county area in KY federally funded through the Ryan 
White HIV/AIDS Treatment and Modernization Act of 2006, and non-federal funds 
through the Commonwealth of KY.  
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The BCC provides expert medical care by physicians, nurses, pharmacists, and other 
clinicians trained to deal with the complex management of a variety of infectious diseases, 
including HIV and related conditions. The clinic enhances access to and retention in primary 
health care and provides support services for Kentuckians living with HIV disease. 
Study Population and Eligibility 
Data for this study were abstracted from the HIV Lab Tracker TM, an electronic 
database located at the BCC. The HIV Lab Tracker TM is an advanced electronic database 
solution for managing patients living with HIV. The electronic database encompasses a 
comprehensive list of information for each patient, which includes demographics, 
laboratory, medication, and clinical data.  
Patients were considered for the study if they were diagnosed with HIV before or 
during the study period and were 18 years of age or older at the time of the study. To obtain 
the patients that met the initial criteria, patients were queried in the database on the 
following criteria: 1) HIV diagnosis date (May 1st, 2011 and earlier) and 2) Age (≥ 18 years). 
The query resulted in 1,485 patients who were pulled from the database and were initially 
eligible for the research study. Patients were included in the study if they sought HIV 
medical care at the BCC during the specified time period, had at least two completed clinic 
visits (intake visit and subsequent clinic visit), had at least 6 months of follow-up time, and 
had the appropriate dates recorded (Clinic visits, HIV Diagnosis, AIDS diagnosis). Of the 
1,485 patients pulled from the database, 1,358 (91%) patients were included for follow-up.  
 The patients included in the study were all followed at 6-month intervals from their 
initial start date to the end of the follow-up period. Patients, whose initial start date came 
before the beginning of the study period (January 1st 2003), were followed from their first 
completed clinic visit in the time frame.  During each 6-month period, the following 
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information was observed: the number of completed clinic visits, diagnoses of new 
infections/diseases (e.g. AIDS, opportunistic infections, Hepatitis C, non-HIV related 
comorbidities), number of hospitalizations, and/or death.  
Study Measures 
 Baseline and clinical characteristics were abstracted from the medical charts. Race 
was categorized into white and non-white. Mode of transmission was categorized as 
heterosexual contact, injection drug use (IDU), men who have sex with men (MSM) and 
other. Insurance status at baseline was categorized into no insurance, Medicaid, Medicare, 
and private.  A history of illicit drug use included individuals that reported use of cocaine, 
meth, and/or marijuana. A concurrent HIV/AIDS diagnosis was defined as an AIDS 
diagnosis within 30 days of an HIV diagnosis. Because the VL at baseline was measured in 
copies/ml and was not normally distributed, the results were transformed into log 
copies/ml. Death was obtained from the medical charts as well as the social security death 
index. For this index, each name and social security number were entered into a database to 
determine date of death. 
For each patient in the study, the number of comorbid conditions diagnosed was 
observed every 6 months as well as the number of visits completed. A clinic visit was 
defined as an HIV medical outpatient care visit. Since laboratory tests were ordered by the 
HIV care physicians during every clinic visit, VL and CD4+ cell count measurements were 
used as surrogate clinic visits.  The non-HIV related comorbidities were defined as the seven 
most commonly diagnosed conditions at baseline among the patients in the study (Table 
4.1). The comorbidities used in the analysis included renal disease, cancer (non-AIDS 
defining), cardiovascular (hypertension, heart disease, and coronary artery disease), 
cerebrovascular (stroke), respiratory (chronic obstructive pulmonary disease (COPD) and 
 
59 
 
asthma), diabetes, and mental health (depression). AIDS defining illnesses (ADIs) were 
observed at baseline and during each six month interval. The ADIs were defined using the 
1993 revised classification system for HIV infection (Table 4.1).77 Another condition 
collected was the diagnosis of Hepatitis C virus. All conditions were abstracted through the 
medical charts. Non-HIV related comorbidities and ADIS were treated as dichotomous 
variables (presence of any comorbidity/ADIs) and as continuous variables (the total 
number of comorbidities/ADIs diagnosed at each 6 month interval). The conditions were 
observed as continuous variables to determine how retention changes over time as the 
number of comorbid conditions increases. 
Outcome Measures 
 Retention in care was the primary outcome in this study; it was defined as having at 
least one HIV medical outpatient visit within each 6-month interval (visit constancy) 
(yes/no). Visits completed were observed until the end of the study period, death, or lost to 
follow-up. The proportion of 6-month intervals with at least one visit was calculated for 
each patient; patients were divided into four groups based on the percentage of 6-month 
intervals with at least one visit. The groups were optimal retainers (100%), suboptimal 
retainers (99% - 75%), sporadic retainers (74% - 50%) and poor retainers (<50%). 21 
Statistical Analysis 
 Data were analyzed using SAS version 9.3 (Cary, NC). Descriptive statistics were 
calculated to describe the study population with means and standard deviations calculated 
for all continuous variables and frequencies and percentages calculated for all categorical 
variables. For the bivariate analysis, ANOVAs and chi-square tests of independence were 
employed to determine differences in retention groups for continuous and categorical 
variables, respectively. 
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 The proportional odds assumption was assessed using the score test to determine 
whether the odds ratios can be interpreted as constant across the retention in care cut 
points and a proportional odds model could be employed.80 Since the assumption was not 
valid, a multinomial logistic regression was used comparing different levels of retention to a 
base level (optimal retention). The multinomial regression analysis was employed to 
determine if comorbid conditions and other factors were associated with suboptimal, 
sporadic, and poor retention compared to optimal retention. Variables with p-values ≤0.15 
in the bivariate analysis and confounding variables (based on previous literature) were 
included in the original model. Variables that did not appear to have an effect on the 
outcome or comorbid conditions were removed from the model. Akaike information criteria 
(AIC) were used to determine which model to use and Hosmer and Lemeshow goodness of 
fit test was produced to determine the fit of the model. In order to determine how the 
number of comorbidities diagnosed predicts retention, ADIs and non-HIV related 
comorbidities were observed as the sum of conditions diagnosed in the first multinomial 
regression. In the second multinomial regression model, each comorbid condition was 
included separately to determine the association between each specific condition while 
controlling for the other variables included in the model.  
 A generalized linear mixed model (GLMM) was used to determine the predictors 
that affect retention over time, in particular, the presence of one or more comorbid 
conditions. GLMMs have been used in research as an alternative way to fit a longitudinal 
model to non-normal data.80,89 In this study, the dependent variable of interest was 
retention to care (yes/no). A GLMM was chosen for the analysis of this study as it has the 
flexibility to specify random effects and also generate subject-specific parameter 
estimates.80,89 Fixed effects (i.e. age, race, sex, health insurance, and Hepatitis C) and random 
effects were included in the model. Random variation between patients was accounted for 
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using random intercepts. In order to obtain a likelihood function for the observed data, the 
random effects have to be integrated out. The integral approximation method allows for the 
approximation of the log likelihood, which allows for likelihood ratio tests to be performed 
among nested models and computation of likelihood-based fit statistics. The integral 
approximation was performed using the Gauss-Hermite Quadrature method. The 
covariance structure employed for this model was the variance component as it models a 
different variance component for each random effect.  
The random-intercept model estimates the probability of being retained over time; 
variables with a p-value ≤0.15 in the bivariate analysis were initially included in this model. 
Two GLMMs were performed for this analysis. The first model included each of the seven 
comorbid conditions while controlling for the other variables. The second model included 
the number of comorbidities diagnosed as a continuous variable, which observed the sum of 
the number of conditions diagnosed during each patient-care interval. Age, number of 
comorbidities diagnosed, and number of ADIS diagnosed were included in the models as 
time-varying variables.  AICs and likelihood ratio tests were used to determine which model 
was the best model and p-values <0.05 were regarded as statistically significant. Each 
model controlled for race, age, history of tobacco use, insurance type, history of Hepatitis C, 
and history of illicit drug use.  
Results 
Demographic and Clinical Characteristics of the Study Population 
 For the entire sample, the mean age at initiation was 38.2 ± 10.1 years, 81.2% were 
men, 70% were white, and the majority of the patients had MSM as their transmission 
category (57%). Approximately 49% lived below the federal poverty level and 27% had a 
history of illicit drug use (Table 4.2). 
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 The majority of the patients entered the study with no insurance (42.6%) and only 
25.8% had private insurance. Over half (53.3%) of the sample acquired AIDS during the 
study period, with 25% entering care with a concurrent HIV/AIDS diagnosis, and 
approximately 13% had a hepatitis c diagnosis. The majority of the sample was prescribed 
HAART during the course of the study period (84.5%) (Table 4.2). 
Comorbidities and other Factors Associated with Rates of Retention 
 The average follow-up time for the study population was 5.75 ± 2.65 years (median 
= 6.20) years and the average number of completed visits during the 9-year study period 
was 39.6 ± 39.8 clinic visits (median = 28.0) (data not shown). Of the 1,358 Patients who 
were seeking HIV medical care at the BCC during the specified time period, only 48.6% were 
optimal retainers, while 19.1% were poor retainers (Table 4.2). In the bivariate analysis, 
optimal retainers were more likely white compared to non-whites (50.7% versus 43.3%, 
p<0.0001), living above the poverty level compared to those below the poverty level (59.6% 
versus 43.1%, p<0.0001), non-smokers compared to smokers (54.3% versus 43.0%, p = 
0.0003), and those with private insurance compared to those with no insurance or Medicaid 
(53.2% versus 46.4%, 41.5%, respectively, p=0.004) (Table 4.2). 
 During the study period, 882 non-HIV related comorbidities were diagnosed in 610 
(44.9%) patients, with approximately 31% of those having two or more comorbidities 
diagnosed. Of the 610 patients that had a comorbidity condition diagnosed, 11% had a 
comorbidity condition only at baseline and approximately 34% were diagnosed with a 
comorbidity condition during the study period.  Depression (430 diagnoses) was the most 
prevalent comorbidity, followed by respiratory disease (110), diabetes (92), and 
cardiovascular disease (76) (Table 4.3). 
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 The bivariate analysis suggested that patients with non-HIV related comorbidities 
were more likely to be optimal retainers compared to those without these comorbidities 
(55.1% versus 43.2%, p <0.0001). Patients with cancer, cardiovascular, diabetes, or mental 
health disorders were more likely to be optimal retainers compared to their counterparts 
(Table 4.3).The non-HIV related comorbidities were divided into three groups (none, one, 
and two+) and figure 4.1 shows that those patients with two or more comorbidities were 
more likely to be optimal retainers compared to those with one or no comorbidity (65.5% 
versus 50.6% and 43.3%, respectively, p <0.0001), and patients with no comorbidity were 
more likely to be poor retainers compared to those with one or two or more comorbidities 
(25.0% versus 14.5% and 5.8%, respectively, p<0.0001) (Figure 4.1). This suggests a dose-
response relationship between the number of comorbid conditions diagnosed and optimal 
and poor retention.  
 Table 4.4 presents the multinomial logistic regression results for factors predicting 
retention to care categories. Compared to optimal retention, suboptimal retainers were at 
an increased odds among the ≤24 year age group (OR = 2.23; 95% CI = 1.21-4.11), 25-34 
year age group (OR = 2.38; 95% CI = 1.55-3.67), and 35-44 year age group (OR = 1.52; 95% 
CI =1.03-2.24) compared to the >44 year age group. The odds of suboptimal retention, 
compared to optimal retention, was significantly higher among heterosexuals (OR = 1.68; 
95% CI = 1.09-2.60) compared to MSM, those living below the poverty level (OR = 1.92; 
95% CI = 1.32-2.79) compared to those above the poverty level, patients with a history of 
smoking (OR = 1.54; 95% CI = 1.13-2.09) compared to those who were smoke free, and 
those with an AIDS diagnosis (OR = 1.75; 95% CI = 1.18-2.59). Suboptimal retention was 
significantly less likely among females (OR = 0.56; 95% CI = 0.34-0.91) compared to males. 
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Sporadic retention, compared to optimal retention, had significantly higher odds 
among those aged 25-34 years (OR = 2.21; 95% CI = 1.30-3.75) compared to those aged >44 
years, those living below the federal poverty level (OR = 2.26; 95% CI = 1.40-3.67), and 
those with a history of Hepatitis C (OR = 1.91; 95% CI =1.10 – 3.30). Poor retention, 
compared to optimal retention, was at significantly higher odds among non-whites (OR = 
1.80; 95% CI = 1.23-2.63) compared to whites, younger individuals, tobacco users (OR = 
1.57; 95% CI = 1.10-2.23), non-insurers (OR = 1.67; 95% CI = 1.04-2.70) and Medicaid (OR = 
2.21; 95% CI = 1.21-4.02) compared to private insurers, and those with CD4+cell counts 
<200 (OR = 2.29; 95% CI = 1.29-4.08) compared to those with CD4+ cell counts >350 at 
baseline (Table 4.4).  
The results of the multinomial regression show that having one or more non-HIV 
related comorbidity was predictive of retention to HIV medical care. For suboptimal, 
sporadic, and poor retention, the odds of having any of the studied comorbidities decreased 
by 0.82 (95% CI = 0.69-0.99), 0.73 (95% CI = 0.56-0.94), and 0.63 (95% CI = 0.48-0.81), 
respectively compared to optimal retention (Table 4.4). This data indicated that patients 
having any of the studied comorbidities had an increased chance of being in optimal care. 
Observing the non-HIV related comorbidities separately in the multinomial model (Figures 
4.2 – 4.4); sporadic retainers, compared to optimal retainers, were at lower odds among 
those patients diagnosed with diabetes (OR = 0.31; 95% CI = 0.11-0.91) (Figure 4.2). 
Compared to optimal retainers, poor retainers were at lower odds among those individuals 
diagnosed with diabetes (OR = 0.32; 95% CI = 0.10-0.98) and depression (OR = 0.61; 95% CI 
= 0.40-0.93) (Figure 4.3). Although not significant, compared to optimal retainers, 
suboptimal, sporadic, and poor retainers were at increased odds among those with a 
respiratory comorbid condition (Figures 4.2 – 4.4).  
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Factors Associated with Retention over Time 
The median number of 6-month periods observed for each individual was 11.0 (IQR: 
5, 16). Figure 4.5 shows the percentage of individuals who retained (at least one visit) in 
each 6-month interval. At the start of the study, there was 100% retention among the 
individuals seeking care, but as time progressed, the percent of individuals retained in care 
decreased. Over the course of the study period, the percentage of patients retained in care 
was higher among those with at least one non-HIV related comorbid condition compared to 
those without a comorbid condition (Figure 4.6). Overall the average percentage of 6-month 
intervals with at least one visit among the entire cohort was 77.6 ±29.9% (median = 94.1).  
The average percentage of 6-month intervals with at least one visit was higher for those 
individuals with two or more comorbid conditions (88.8 ±21.7%) compared to those with 
one condition (82.1 ±25.7%) or none (72.5 ±32.6%) (p<0.0001) (Figure 4.7).  
Figure 4.8 presents the percentage of individuals who retained through each 
interval categorized by when a comorbid condition was diagnosed. Patients with a 
comorbid condition diagnosed at baseline and another condition diagnosed during the 
study period were more likely to be retained in care compared to the other groups. The 
figure also shows that while all four groups had a decrease in the percent retained in the 
early stages of the follow-up period, those with both a baseline and study comorbid 
condition had slight increases in the percent retained. Figure 4.9 presents the percent 
retained for each comorbid condition separately. Patients with cancer, renal disease, 
diabetes, and cerebrovascular conditions appeared to have increased retention throughout 
the study period. 
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The GLMMs estimated how non-HIV related comorbidities were associated with 
retention over time. Table 4.5 presents the associations between each comorbid condition 
and retention over time. Controlling for all variables included in the model, a patient 
diagnosed with depression during the study period, were at an increased odds of optimal 
retention over time (OR = 3.80; 95% CI = 2.54 – 5.68). Individuals with diagnosed diabetes 
during the study period had 5.71 (95% CI = 2.49 – 13.16) times the odds of improved 
retention compared to those without diabetes. A patient diagnosed with cancer or a 
cardiovascular condition had 3.89 (95% CI = 1.54 – 9.80) and 3.16 (95% CI = 1.33-7.52) 
times the odds, respectively of improved retention over time compared to one without 
cancer or a cardiovascular condition.  
Table 4.6 presents the GLMM which includes, the number of non-HIV related 
comorbidities as a time-varying covariate. As the number of non-HIV related comorbid 
conditions diagnosed increased during the study, the odds of retention increased (OR = 
2.28; 95% CI = 1.83-2.71), while controlling for the other variables in the model. As the 
number of ADIs diagnosed during the study increased for an individual, the odds of 
retention over time increased (OR = 1.84; 95% CI = 1.45 – 2.27). Throughout the follow-up 
period, non-whites compared to whites had a difficult time retaining in care as these 
individual were at decreased odds of retaining over time (OR = 0.36; 95% CI = 0.24-0.55). 
While controlling for the other variables included in the model, individuals without 
insurance or Medicaid were 0.45 (95% CI = 0.28-0.72) and 0.30 (95% CI = 0.17-0.55) times 
the odds, respectively of retaining in care over time. Lastly, having a Hepatitis C diagnosis 
meant worse retention over time compared to those without a Hepatitis C diagnosis (OR = 
0.51; 95% CI = 0.29-0.89). 
  
 
67 
 
Discussion 
  Retention in HIV medical care was observed among an HIV population seeking care 
at a Ryan White funded clinic. The purpose of this study was to determine the predictors of 
retention and to shed light on the impact comorbidities have on retention to care over time. 
This study is one of the few studies to focus specifically on a Ryan White population as well 
as observe a time period longer than 1 to 2 years. Of the 1,358 individuals who were 
included in the study, only 48.6% had optimal retention (a visit in every 6-month interval). 
This statistic is significantly below the national average as it is suggested that 
approximately 73% of clients enrolled in Ryan White funded clinics and 60% of patients 
enrolled in other medical clinics are consistently retained in HIV medical care13,59.  
 With the multinomial logistic regression, we were able to determine what factors 
predicted suboptimal, sporadic, or poor retention compared to optimal retention. We found 
that age at baseline, non-whites, heterosexual transmission, low income, tobacco use, 
Hepatitis C, and lower CD4+ cell counts were predictive of patients being in at least one less 
than optimal group of retention. Controlling for socioeconomic status, race, insurance 
status, disease severity, and younger age were strongly predictive of all three retention 
groups. Individuals who were aged 25-34 years were almost 4 times the odds of being poor 
retainers compared to those aged >44 years. This finding agrees with other studies as 
researchers have shown that older PLWHA’s are more likely to retain in care compared to 
younger individuals 19,22,28. It is important to focus on the younger HIV population as this age 
group makes up the majority of individuals diagnosed and living with HIV.72,90-92 Retention 
interventions should be set in place that target the younger HIV population as this may 
increase retention and reduce the risk of transmission.  
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 The finding that blacks and Hispanics were at greater odds of poor retention, even 
after controlling for socioeconomic status (income and insurance) and other variables, is 
discouraging. Multiple studies have suggested that blacks and Hispanics have significant 
difficulty retaining in HIV medical care compared to whites. 16,21,22,25,28,29,32,33,93 The BCC 
provides assistance to those individuals who may be of low economic status by providing 
programs such as the AIDS drug and assistance programs.  Unfortunately, this study did not 
consider potential barriers to retention like transportation, social stigma related to 
HIV/AIDs, or distrust of the medical system, as this has been shown to be a major factor for 
poor retainers, especially among minorities.63,64 Further research needs to be done to 
understand the factors that contribute to blacks and Hispanics having poor retention. This 
disparity in care may be a major reason why blacks and Hispanics living with HIV/AIDS 
have worse HIV outcomes compared to whites. 22,25 
 Although individuals seeking HIV medical care at a Ryan White funded clinic are 
provided opportunities and assistance to maintain the management of their HIV infection at 
little to no costs, socioeconomic status was significantly predictive of suboptimal to  poor 
retention. Individuals living below the federal poverty line were more likely to be 
suboptimal and sporadic retainers and those with no insurance or only Medicaid had 
greater odds of being poor retainers compared to their counterparts. This is interesting as 
these individuals are missing their opportunities to reduce their risk of disease progression. 
The costs of treatment were not considered in this study, but a few possibilities may explain 
this result. Individuals of low socioeconomic status may not have optimal retention due to 
lack of transportation, ‘leave’ time for work, or child care services.63,64,66 Transportation may 
be a key factor to poor retention as a majority of the patients that seek care are from rural 
areas in KY. It is pertinent to understand the barriers that prevent patients from retaining in 
care and to develop interventions which will engage patients into care.  
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 It is estimated that approximately 50% of PLWHA have comorbidities such as 
cancer, heart disease, mental health, and renal disease, and that substance abuse and 
alcoholism are also highly prevalent among PLWHAs.59 Approximately 45% of the 
individuals in this study had a least one non-HIV related comorbidity. Of the six 
comorbidities included in the analysis, depression was the most prevalent, followed by 
respiratory, diabetes, and cardiovascular. The results of the study suggest that having one 
or more comorbidity actually facilitates retention in care. Individuals with at least one 
comorbid condition were more likely to be optimal retainers compared to those individuals 
who were ‘healthier.’ Approximately 31% of those with comorbid conditions had two or 
more conditions diagnosed during the study period. The multinomial regression suggest 
that as the number of comorbid conditions increased, the less likely they were to be 
suboptimal, sporadic, or poor retainers. This finding mirrors the findings of Giordano et al., 
which showed that individuals with comorbid conditions were more likely to retain in 
care.22  
Fleming et al showed that individuals living with multiple morbid conditions were 
more likely to seek colorectal screening compared to those with no condition diagnosed.94 
Although Fleming et al’s study focused on cancer screening, their results are similar to ours 
which shows that these individuals are more likely to seek proper care and prevention 
measures, perhaps because they have multiple chronic conditions to worry about.  Our 
interpretation of these studies is that individuals with comorbid conditions are already 
seeking care providing the opportunity for physicians to emphasize the importance of being 
retained in care to manage their medical conditions.  
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 Individuals with diabetes and mental health disorders diagnosed during the study 
period had higher odds of optimal retention. This finding contradicts some researcher’s 
findings as they suggest that individuals with mental health disorders like depression have 
greater difficulty retaining in HIV care.62 We did, however, find that individuals diagnosed 
with depression prior to initiation of HIV medical care (baseline) were less likely to be 
optimal retainers compared to those who were diagnosed during the study period. 
Individuals who are diagnosed with HIV and have a prior mental illness may need to be 
referred to mental health services immediately as this may help promote and increase 
retention in care. Researchers have shown than individuals that take part in ancillary 
services like mental health services, are more likely to optimally retain in care.53-55,67,70 A 
marginally significant result was that those individuals with respiratory illnesses (Asthma 
and COPD) had greater odds of sporadic and poor retention. This finding should be 
examined further regarding why these individuals are failing to retain HIV/AIDS care. To 
our knowledge, this is the first study to observe comorbid conditions separately regarding 
the impact on retention in care.   
 The GLMM was performed to understand how retention changes over time for this 
Ryan White population. The results showed that over time, as the number of comorbid 
conditions diagnosed increased the more likely an individual was to retain in care. Having 
multiple ADIs diagnosed during the study period was also predictive of improved retention. 
Observing each comorbid condition separately, it was shown that individuals with diabetes, 
cancer, cardiovascular, and depression conditions had much greater odds of retention 
compared to those without those conditions. This implies that individuals who are 
‘healthier’ are not consistently engaged in care. One could argue that PLWHA who feel 
‘healthy’ find it unnecessary to seek care, whereas those who are sicker feel the need to 
engage in care more frequently. Some research supports an alternative hypothesis that the 
 
71 
 
healthy (not the sick) seek care more frequently, maintaining their ‘healthy’ status.50 
Further research should be conducted on this ‘healthy’ population to determine how poor 
retention affects specific short and long-term HIV outcomes like viral load suppression, 
progression to AIDS, or death. 
 It is difficult for individuals with a history of Hepatitis C to be retained in care. 
Retention to HIV medical care worsens over time for individuals co-infected with Hepatitis 
C. Some also argue that individuals with substance abuse problems are less likely to retain 
in care, perhaps because there is a strong correlation between substance abusers and 
Hepatitis C among PLWHA.59 Nonetheless, in our study, there was no significant interaction 
between individuals using illicit drugs and Hepatitis C, although those with Hepatitis C did 
have difficulties maintaining retention.  
We showed a decreased retention over time among those who did not have any 
comorbidity. In order for the clinical management of HIV to be successful it is critical for 
individuals to remain engaged in care. It was shown in chapter 3 that approximately 16% of 
the sample had gaps in care that were >12 months. Re-engaging these individuals that fall 
out of care should be a major priority among clinicians and public health researchers. 
Multiple strategies and interventions should be developed that seek out these individuals 
and reintegrate them to HIV care. To our knowledge there has not been any study to 
definitively show the best strategy in reengaging these individuals. 
This study has both strengths and limitations.  For example, the chart review was 
only able to assess whether patients had been diagnosed with comorbid conditions but not 
the severity of these conditions; thus we were unable to determine the significance or 
magnitude of any relationship between comorbidity severity condition and retention to 
care. We also did not observe ancillary services such as mental health programs, 
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transportation services, and case managers. The services could confound the relationship 
between retention in care over time and comorbid conditions. The Ryan White population 
enrolled in this study may not be generalizable to other PLWHA that are not enrolled in 
Ryan White programs, so these results should be interpreted and compared with caution. 
Since our definition of a clinic visit includes only visits from HIV care providers, retention in 
care may be underestimated for this study population. Although this may be so, the 
definition is consistent with other studies which defined retention in HIV medical care.14 On 
a related note, individuals were excluded from the study if they did not have at least two or 
more clinic visits completed during the specified time period. This exclusion could lead to 
an underestimation of poor retainers. The number excluded due to this criterion was small, 
and there were no significant differences between the cohorts.  
The major strengths of our study are the relatively large sample size, compared to 
other studies that investigate retention in care and the lengthy follow-up period (9years) 
compared to most other studies of shorter duration (1-3 years).13,22 
Conclusion 
 The current study showed that younger age, non-whites, no insurance, and those 
with a history of AIDS were more likely to have poor retention, while individuals with non-
HIV related comorbidities were less likely to have poor retention. It was suggested that over 
time, retention in care decreases slightly among this Ryan White population. Over time, 
patients with comorbid conditions had improved retention in HIV medical care. 
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 Having multiple ADIs diagnosed during the study period was also predictive of 
improved retention. Not retaining in HIV care can pose significant problems for these 
individuals as it can possibly lead to medication resistance, progression to AIDS or even 
death. More research needs to be done to identify factors that improve retention over time 
and to quantify the relative impact of these factors.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Timothy Nathaniel Crawford 2012 
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Table 4.1. List of conditions observed among those seeking 
HIV medical care at the BCC: 2003-2011 
Condition   Condition 
AIDS-defining 
Illnesses/Conditions 
 
Non-HIV related 
comorbidities 
Candidiasis, pulmonary 
 
Renal Disease 
Candidiasis, esophageal 
 
Cardiovascular  
Cervical Cancer, 
invasive 
 
Cerebrovascular  
  Respiratory 
Coccidioidomycosis 
 
Diabetes 
Cytomegalovirus 
 
Cancer 
Encephalopathy 
 
Mental Health (Depression) 
Herpes Simplex Virus 
(HSV) 
  Histoplasmosis 
 
Other 
Kaposis Sarcoma 
 
Hepatitis C 
Lymphoma, Burkitt's  
  Mycobacterium avium 
complex (MAC) 
 
Behavioral 
Mycobacterium 
tuberculosis (TB) 
 
History of Tobacco Smoke 
Pneumocystis carinii 
pneumonia (PCP) 
 
History of Illicit Drug Use 
(Marijuana, Cocaine, and 
Crystal Meth) 
Progressive Multifocal 
Leukoencephalopathy 
(PML) 
  Toxoplasmosis 
  Wasting Syndrome   
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Table 4.2. Socio-demographic and Clinical Characteristics Among Adults Diagnosed and Living 
with HIV/AIDS by the Proportion of 6 month intervals with at Least One Clinic Visit : 2003 - 
2011 
  Total 
Optimal 
Retention          
n (%) 
Suboptimal 
Retention               
n (%) 
Sporadic 
Retention                 
n (%) 
Poor 
Retention            
n (%) p 
Total 1358 660 (48.6) 281 (20.7) 158 (11.6) 259 (19.1) 
 Sex 
      Female 256 (18.9) 128 (50.0) 48 (18.8) 33 (12.9) 47 (18.4) 0.8 
Male 1102 (81.2) 532 (48.3) 233 (21.1) 125 (11.3) 212 (19.2) 
 Race 
      Non-White 404 (29.8) 175 (43.3) 69 (17.1) 54 (13.4) 106 (26.2) <0.001 
White 952 (70.2) 483 (50.7) 212 (22.3) 104 (10.9) 153 (16.1) 
 Age at Baseline 
      ≤24 yrs 136 (10.0) 56 (41.2) 28 (20.6) 21 (15.4) 31 (22.8) <0.001 
25 - 34 yrs 362 (26.7) 143 (39.5) 86 (23.8) 48 (13.3) 85 (23.5) 
 35 - 44 yrs 504 (37.1) 245 (48.6) 108 (21.4) 53 (10.5) 98 (19.4) 
 >44 yrs 356 (26.2) 216 (60.7) 59 (16.6) 36 (10.1) 45 (12.6) 
 Age mean years 
(std) 38.2 (10.1) 39.7 (10.2) 36.9 (9.7) 37.2 (10.5) 36.4 (9.3) <0.001 
Mode of 
Transmission 
      Heterosexual 385 (28.4) 178 (46.2) 79 (20.5) 44 (11.4) 84 (21.8) 0.06 
IDU 122 (9.0) 55 (45.1) 22 (18.0) 20 (16.4) 25 (20.5) 
 Other 72 (5.3) 26 (36.1) 23 (31.9) 11 (15.3) 12 (16.7) 
 MSM 777 (57.3) 401 (51.6) 157 (20.2) 82 (10.6) 137 (17.6) 
 Employment 
Status  
     Employed 501 (45.8) 276 (55.1) 113 (22.6) 51 (10.2) 61 (12.2) 0.07 
Unemployed 402 (36.0) 192 (47.8) 91 (22.6) 46 (11.4) 73 (18.2) 
 Other 215 (19.2) 123 (57.2) 41 (19.1) 26 (12.1) 25 (11.6) 
 Incomea 
      ≤10,000 662 (48.8) 285 (43.1) 166 (25.1) 97 (14.7) 114 (17.2) <0.001 
>10,000 446 (32.8) 266 (59.6) 91 (20.4) 36 (8.1) 53 (11.9) 
 History of 
Tobacco Use 
      Yes 686 (50.5) 295 (43.0) 163 (23.8) 90 (13.1) 138 (20.1) <0.001 
No 672 (49.5) 365 (54.3) 118 (17.6) 68 (10.1) 121 (18.0) 
 History of Illicit 
Drug Use 
      Yes 365 (26.9) 160 (43.8) 88 (24.1) 55 (15.1) 62 (17.0) 0.01 
No 993 (73.1) 500 (50.4) 193 (19.4) 103 (10.4) 197 (19.8)   
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Table 4.2. Continued 
  Total 
Optimal 
Retention          
n (%) 
Suboptimal 
Retention               
n (%) 
Sporadic 
Retention                 
n (%) 
Poor 
Retention            
n (%) p 
Insurance Type 
      No Insurance 569 (42.6) 264 (46.4) 111 (19.5) 71 (12.5) 123 (21.6) 0.004 
Medicaid 212 (15.9) 88 (41.5) 49 (23.1) 27 (12.7) 48 (22.6) 
 Medicare 211 (15.8) 120 (56.9) 41 (19.4) 22 (10.4) 28 (13.3) 
 Private 344 (25.8) 183 (53.2) 80 (23.3) 37 (10.8) 44 (12.8) 
 Concurrent 
Diagnosis 
      Concurrent 341 (25.1) 15 (54.3) 73 (21.4) 37 (10.9) 46 (13.5) 0.01 
Non-Concurrent 1017 (74.9) 475 (46.7) 208 (20.5) 
121 
(11.9) 213 (20.9) 
 History of AIDS 
Diagnosis 
      Yes 724 (53.3) 354(48.9) 176 (24.3) 79 (10.9) 115 (15.9) <0.001 
No 634 (46.7) 306 (48.3) 105 (16.6) 79 (12.5) 144 (22.7) 
 History of 
Hospitalizations 
      Yes 738 (54.3) 403 (54.6) 158 (21.4) 84 (11.4) 93 (12.6) <0.001 
No 620 (45.7) 257 (41.5) 123 (19.8) 74 (11.9) 166 (26.8) 
 Hepatitis C 
      Yes 172 (12.7) 67 (39.0) 38 (22.1) 31 (18.0) 36 (20.9) 0.01 
No 1186 (87.3) 593 (50.0) 243 (20.5) 
127 
(10.7) 223 (18.8) 
 HAART Use 
      
Yes 1148 (84.5) 589 (51.3) 264 (23.0) 
125 
(10.9) 170 (14.8) <0.001 
No 210 (15.5) 71 (33.8) 17 (8.1) 33 (15.7) 89 (42.4) 
 CD4+ Cell Countsa 
     <200 390 (28.7) 188 (48.2) 80 (20.5) 41 (10.5) 81 (20.8) <0.001 
200 - 350 150 (11.1) 82 (54.7) 33 (22.0) 19 (12.7) 16 (10.7) 
 >350 458 (33.7) 237 (51.8) 124 (27.1) 48 (10.5) 49 (10.7) 
 Initial Viral 
Load mean log 
copies (std) 6.75 (3.05) 6.9 (3.2) 6.6 (3.0) 6.3 (2.9) 6.7 (2.9) 0.19 
aIndividuals with missing information were included in the calculation of percentages 
Note: P values obtained using ANOVA  and chi-square tests of independence for continuous 
and categorical variables, respectively 
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Table 4.3. Presence of Non-HIV related Comorbidities among 1358 Individuals Diagnosed and 
Living with HIV/AIDS by the Proportion of 6 Month Intervals with at Least one Clinic Visit: 
2003-2011 
  Total 
Optimal 
Retention          
n (%) 
Suboptimal 
Retention               
n (%) 
Sporadic 
Retention                 
n (%) 
Poor 
Retention            
n (%) p 
Any 
Comorbidity 
      Yes 610 (44.9) 336 (55.1) 140 (23.0) 62 (10.2) 72 (11.8) <0.001 
No 748 (55.1) 324 (43.2) 141 (18.9) 96 (12.8) 187 (25.0) 
        Comorbidity Types 
     Renal  
      Yes 28 (2.1) 17 (60.7) 7 (25.0) 1 (3.6) 3 (10.7) 0.29 
No 1330 (97.9) 643 (48.4) 274 (20.6) 157 (11.8) 256 (19.3) 
 Cancer 
      Yes 65 (4.8) 43 (66.2) 10 (15.4) 4 (6.2) 8 (12.3) 0.03 
No 1293 (95.2) 617 (47.7) 271 (21.0) 154 (11.9) 251 (19.4) 
 Cardiovascular  
      Yes 76 (5.6) 50 (65.8) 17 (22.4) 7 (9.2) 2 (2.6) 0.001 
No 1282 (94.4) 610 (47.6) 264 (20.6) 151 (11.8) 257 (20.1) 
 Cerebrovascular 
     Yes 17 (1.3) 11 (64.7) 3 (17.7) 2 (11.8) 1 (5.9) 0.46 
No 1341 (98.8) 649 (48.4) 278 (20.7) 156 (11.6) 258 (19.2) 
 Respiratorya 
      Yes 110 (8.1) 49 (44.6) 30 (27.3) 16 (14.6) 15 (13.6) 0.13 
No 1248 (91.9) 611 (49.0) 251 (20.1) 142 (11.4) 244 (19.6) 
 Diabetes 
      Yes 92 (6.8) 62 (67.4) 20 (21.7) 4 (4.4) 6 (6.5) <0.001 
No 1266 (93.2) 598 (47.2) 261 (20.6) 154 (12.2) 253 (20.0) 
 Mental Healthb 
      Yes 430 (31.7) 241 (56.1) 97 (22.6) 44 (10.2) 48 (11.2) <0.001 
No 928 (68.3) 419 (45.2) 184 (19.8) 114 (12.3) 211 (22.7)   
Note: P values obtained using chi square tests of independence 
aRespiratory disease consists of individuals with diagnosed Asthma or COPD 
bMental Health includes Depression 
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Table 4.4. Multinomial Logistic Regression of the Predictors of Retention to Medical 
Care among 1358 Individuals Living with HIV/AIDS : 2003 - 2011 
 
Suboptimal 
retention vs. 
optimal retention 
Sporadic 
retention vs. 
optimal retention 
Poor retention vs.                          
optimal retention 
Variable aOR 95% CI aOR 95% CI aOR 95% CI 
Sex 
      Female vs. Male 0.56 0.34-0.91 0.79 0.44-1.40 0.6 0.35-1.03 
Race 
      Non-White vs. White 0.83 0.57-1.19 1.28 0.84-1.95 1.8 1.23-2.63 
Age at Baseline 
      ≤24 vs. >44 years 2.23 1.21-4.11 2.08 1.03-4.17 2.28 1.15-4.50 
25 - 34 vs. >44 years 2.38 1.55-3.67 2.21 1.30-3.75 3.89 2.34-6.46 
35 - 44 vs. >44 years 1.52 1.03-2.24 1.3 0.80-2.14 2.15 1.35-3.43 
Mode of Transmission 
      Heterosexual vs. MSM 1.68 1.09-2.60 1.35 0.78-2.33 1.54 0.95-2.50 
IDU vs. MSM 0.86 0.47-1.57 1.07 0.55-2.09 0.9 0.45-1.77 
Other vs. MSM 3.15 1.64-6.04 1.89 0.84-4.24 1.1 0.49-2.48 
Income 
      ≤10,000 vs. >10,000 1.92 1.32-2.79 2.26 1.40-3.67 1.48 0.95-2.30 
History of Tobacco Use 
      Yes vs. No 1.54 1.13-2.09 1.45 0.99-2.13 1.57 1.10-2.23 
History of Illicit Drug 
Use 
      Yes vs. No 1.24 0.88-1.76 1.89 0.82-1.91 0.73 0.48-1.11 
Insurance Type 
      No Insurance vs. Private 0.64 0.42-0.97 0.78 0.47-1.30 1.67 1.04-2.70 
Medicaid vs. Private 0.76 0.45-1.31 0.9 0.47-1.73 2.21 1.21-4.02 
Medicare vs. Private 0.57 0.35-0.93 0.79 0.41-1.49 1.21 0.65-2.24 
AIDS Diagnosis 
      Yes vs. No 1.75 1.18-2.59 1.23 0.74-2.04 0.94 0.57-1.53 
CD4+ Cell Counts       
<200 vs. >350 0.56 0.36-0.87 0.96 0.53-1.74 2.29 1.29-4.08 
200 – 350 vs. >350 0.6 0.36-0.98 1.05 0.56-1.99 1.13 0.57-1.99 
History of 
Hospitalizations       
Yes vs. No 0.68 0.49-0.93 0.71 0.48-1.04 0.39 0.26-0.56 
Hepatitis C       
Yes vs. No 1.38 0.84-2.24 1.91 1.10-3.30 1.29 0.74-2.25 
AIDS Defining Illnesses 1.14 0.98-1.33 0.95 0.76-1.18 0.87 0.70-1.09 
Non-HIV Related 
Comorbidity 0.82 
0.69 - 
0.99 0.73 0.56-0.94 0.63 0.48-0.81 
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Table 4.5. Generalized Linear Mixed Model to determine the Association between Comorbid 
Conditions and Retention over time among patients seeking care at the BCC: 2003-2011 
Comorbid Condition 
Total (%) Unadjusted 
OR 95% CI 
Adjusted 
OR 95% CI 
Depression  (yes vs. no) 430 (31.7) 6.80 4.37-10.64 3.80 2.54-5.68 
Renal Disease (yes vs. no) 28 (2.1) 5.00 1.04-23.81 0.82 0.22-3.13 
Cancer (yes vs. no) 65 (4.8) 6.94 2.41-20.0 3.89 1.54-9.80 
Respiratory (yes vs. no) 110 (8.1) 1.87 0.88-3.94 1.15 0.61-2.18 
Diabetes (yes vs. no) 92 (6.8) 14.29 5.71-35.71 5.71 2.49-13.16 
Cardiovascular (yes vs. no) 76 (5.6) 16.39 6.13-43.48 3.16 1.33-7.52 
Cerebrovascular (yes vs. no) 17 (1.3) 5.29 0.66-41.67 0.75 0.13-4.18 
Note: The model controlled for race, age (in years), history of tobacco use, insurance type, hepatitis c, 
illicit drug use, prescription of HAART, and year of HIV 
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Table 4.6. Generalized Linear Mixed Model to 
determine Retention over time among patients seeking 
care at the BCC: 2003-2011 
Variable aOR 95% CI 
Comorbidities 2.28 1.83-2.71 
AIDS Defining Illnesses 1.84 1.45-2.27 
Race (Non-White versus White) 0.36 0.24 – 0.55 
Age (years) 1.03 1.01-1.05 
Tobacco Use  Yes vs. No 0.65 0.45-0.96 
Insurance Type   
No Insurance vs. Private 0.45 0.28-0.72 
Medicaid vs. Private 0.30 0.17-0.55 
Medicare vs. Private 0.92 0.50-1.68 
Hepatitis C  Yes vs. No 0.51 0.29-0.89 
Illicit Drug Use Yes vs. No 1.04 0.67-1.61 
Note: The GLMM controlled for those initiating HAART 
and the year of HIV diagnosis. 
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Figure 4.1 Status of Retention to HIV Medical Care among those with Multiple Non-
HIV Related Comorbidities: 2003-2011 
 
82 
 
 
  Figure 4.2 Forest plot diagram presenting the odds ratios from the multinomial 
logistic regression for sporadic retention versus optimal retention for each non-HIV 
related comorbid condition 
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Figure 4.3 Forest plot diagram presenting the odds ratios from the multinomial logistic 
regression for poor retention versus optimal retention for each non-HIV related 
comorbid condition 
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Figure 4.4 Forest plot diagram presenting the odds ratios from the multinomial 
logistic regression for suboptimal retention versus poor retention for each non-HIV 
related comorbid condition 
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Figure 4.5 Plot of Retention over the study period among those individuals seeking 
HIV medical care from 2003 to 2011 
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Figure 4.6 Plot of Retention over the study period among those individuals seeking 
HIV medical care with and without a non-HIV related Comorbidity diagnosed 
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Figure 4.7 Plot of retention over the study period among those individuals seeking 
HIV medical care with none (black line), one (blue line), or two+ (red line) non-HIV 
related Comorbidities diagnosed 
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Figure 4.8 Plot of retention over the study period among those individuals 
seeking HIV medical care categorized by when the non-HIV related comorbidity 
was diagnosed. No comorbidity diagnosed (black line), comorbidity diagnosed at 
baseline only (blue line), comorbidity diagnosed only during the study period (red 
line), and comorbidity diagnosed at baseline and during the study period (green 
line) 
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Figure 4.9 Plot of retention over the study period among those individuals seeking HIV medical care by the 
type of non-HIV related comorbidity diagnosed 
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Chapter Five 
Impact of Retention in HIV Medical Care on Time to Viral Load Suppression and Rebound 
among Individuals Initiating HAART 
Introduction 
 Once an individual has been diagnosed with HIV, early linkage to and retention to 
continuous HIV medical care are arguably the two most important components to the 
continuum of HIV healthcare that improve the health outcomes of individuals diagnosed 
and living with HIV.12 It has been suggested that in the United States (U.S.), approximately 
77% of individuals diagnosed with HIV are linked into care within three to six months after 
diagnosis, but only 51% of those that are linked actually remain in care.11 Maintaining 
optimal retention in medical care is required among individuals living with HIV to receive 
full access to all treatment benefits. Poor retention in care after initial linkage can be 
detrimental to an individual’s health as this can delay the initiation of antiretroviral therapy 
and can lead to more detrimental clinical events, like virological failure, AIDS, or 
death.22,25,27,28,85  
 With the major advancements in HIV medical care, HIV has become a manageable 
chronic infectious disease. Initiating highly active antiretroviral therapy (HAART) into the 
clinical management of HIV has been shown to dramatically reduce the morbidity and 
mortality due to HIV, including suppressing viral load (VL) which in turn reduces the risk of 
HIV transmission.24 Gardner et al suggested that approximately 25% of patients who are 
eligible to receive HAART are not receiving therapy due to refusal or failure to initiate 
therapy.12 Of those who are receiving therapy, it is estimated that only 77% have achieved a 
viral suppression throughout the course of their infection. With approximately 15 to 25% of 
individuals without a suppressed VL, it is believed that barriers to achieving viral 
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suppression among individuals who have initiated HAART are poor medication adherence, 
non-persistence, and resistance.12 Although this may be true, failure to maintain optimal 
retention in HIV medical care may play a significant role in the failure to achieve a 
suppressed VL.24  
 Poor retention in care represents an arduous obstacle to achieving viral suppression 
as this has important individual and public health implications. Little is known about the 
impact retention in care has on viral suppression, especially after individuals initiate 
HAART.24,45,47 Understanding retention in care and how it affects health outcomes among 
individuals initiating HAART for the first time is very important. Individuals who have been 
linked to care and initiated HAART for the very first time are at a vulnerable stage in the 
course of their infection, as they are now expected to attend regularly scheduled clinic visits 
and sustain near perfect levels of medication adherence, and these individuals may not be 
prepared for the long-term commitment that is attached to HIV care.     
 A goal of the National HIV/AIDS strategy is to increase the proportion of HIV 
diagnosed persons with undetectable VL by 20%. That means, linking diagnosed persons 
into care, initiating therapy in a timely manner, and maintaining optimal retention 
throughout the course of infection.59 But once an individual has achieved viral suppression, 
it is important that these individuals maintain suppression and avoid viral rebound. 
Achievement and maintenance of viral suppression is related to the long-term efficacy of 
HAART, but a large proportion of patients have viral loads rise above detectable levels over 
time. The rates of VL rebound have been reported to be between 20 and 40%.95-98 High rates 
of VL rebound are typically among individuals with high VLs on starting HAART, but little is 
known on how retention in care impacts the time to virological rebound once suppression 
has been achieved.  
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The purpose of the study is to determine the impact retention in care has on viral 
suppression and rebound after initiating HAART. Employing parametric time to event 
methods, the hypotheses is that poor retention in care after initiation of HAART will delay 
time to viral suppression and shorten the time to viral rebound. This study extends prior 
research as it is one of the first studies to observe retention in care after initiation of HAART 
and to our knowledge is one of the first studies to evaluate the impact of retention on viral 
rebound.    
Methods 
Study Design  
  A retrospective cohort study design, employing a medical chart review, was 
conducted at an academic infectious disease clinic at the University of Kentucky (KY) to 
determine the impact retention in HIV medical care has on the time to viral suppression and 
viral rebound. Patients who sought care between January 1st, 2003 and May 1st 2011, and 
had initiated HAART anytime during the course of their infection, were considered eligible 
for this study, and were followed until December 31st, 2011. In this study, patients were 
followed from initiation of HAART until the event of interest occurred (viral suppression), 
or until the end of the study period (December 31st, 2011) or death. For the patients who 
achieved a viral suppression anytime during the study period, patients were followed from 
the time of suppression until the event of interest occurred (viral rebound), the end of the 
study period, or death. The study was approved by the University of KY Institutional Review 
Board. 
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Study Site 
Individuals diagnosed with HIV and seeking HIV medical care at the 
Bluegrass Care Clinic (BCC) during the study period were considered for inclusion 
into the study. The BCC is a multi-disciplinary HIV care clinic located in an urban 
area in KY, and is the largest of four HIV care providers in a 63 county area in KY 
federally funded through the Ryan White HIV/AIDS Treatment and Modernization 
Act of 2006, and non-federal funds through the Commonwealth of KY. The BCC 
provides expert medical care by physicians, nurses, pharmacists, and other 
clinicians trained to deal with the complex management of a variety of infectious 
diseases, including HIV and related conditions. The BCC is home to approximately 
2,000 active patients, which includes those living with HIV disease. Approximately 
60% of the patient population lives in rural areas in KY. 
Study Population and Eligibility 
Data were abstracted from the HIV Lab TrackerTM electronic database. For the 
current study, patients who were seeking HIV medical care during the study period, were 
≥18 years of age at the time of the study, and had initiated HAART at any time during the 
course of their infection were considered eligible for the study. To be included in the 
current study, patients had to have at least one HIV outpatient medical clinic visit during the 
specified study period (not including initiation of HAART), an initial VL measurement with 
an actual date of result, a subsequent VL measurement with an actual date attached, and a 
follow-up greater than 6 months. Restricting the study to patients that have a follow-up 
greater than 6 months allows time for patients to obtain a subsequent VL measurement so 
suppression can be observed. 
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For the time to viral suppression study, patients that had a VL measurement of <50 
copies/ml at the time of the study were excluded from this analysis. For the time to viral 
rebound study, patients that did not achieve a viral suppression at any time during the 
study were excluded from the analysis. There were 1,166 patients that had initiated HAART 
and were eligible for the study, with 1,108 (95%) having at least one VL recorded. Of the 
1,108 patients with at least one VL recorded, only 973 (88%) patients had a VL with a date 
recorded (Figure 5.1). There were no significant differences between those who did not 
have a date recorded and those who did.  
For time to viral suppression, patients were excluded from the analysis of the study 
if they had achieved a suppressed VL (<50 copies/ml) prior to start of the study or the start 
of HAART. Of the 973 patients with a VL recorded during the study period, 549 (56%) had a 
VL that was >50 copies/ml at initiation of HAART and were included for the analysis. For 
time to viral rebound, patients were excluded from the analysis if they did not achieve a 
viral suppression at any time during the study period. Of the 973 patients, 699 (72%) had 
achieved at least one suppressed VL and was followed to observe viral rebound. 
Study Measures 
Demographic and clinical data were abstracted from the medical records for the 
patients included in the study. Demographic information collected during the study 
included date of birth, sex, race/ethnicity (white/nonwhite), marital status, employment 
status, insurance status, poverty level (<100% below federal poverty level), history of 
tobacco and illicit drug use (yes/no), and transmission category (Men who have Sex with 
Men (MSM), Heterosexual contact, Injection Drug Users (IDU), and other). The clinical 
characteristics obtained included CD4+ cell counts, viral loads, concurrent HIV/AIDS 
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diagnosis, history of hepatitis c, history of hospitalizations, history of non-HIV related 
comorbidities, date of HAART initiation, and date of death.  
Date of death was abstracted from the electronic medical records for those patients 
who sought care at the BCC during the study period. The Social Security Death Index was 
used to determine date of death for those patients who were lost to follow-up or had moved 
out of the service area. Each patient was manually entered into the database to determine 
date of death and was matched by name, date of birth, and social security number.  
Retention in Care Measure 
According to current Department of Health and Human Services guidelines, newly 
diagnosed individuals should seek HIV medical primary care at least every 3 to 4 months 
until their immunological and virological response has been maintained at the appropriate 
levels, and then once every 6 months after that.23 Patients living with HIV who initiate 
HAART should be monitored consistently, so the patient can maintain adherence and viral 
suppression. Using visit constancy as the measure of retention in care for this study, 
patients’ retention was dichotomized in optimal (100%) or non-optimal retainers (<100%). 
Outcome Measures 
The primary endpoint of the study was viral suppression, and was defined as having 
an HIV RNA level of <50 copies/ml. Time to viral suppression (years) was defined as the 
time from the initiation of HAART to the time of the first suppressed VL. Viral rebound was 
the secondary endpoint for this study and included only the individuals who achieved VL 
suppression at any time during the study period and was defined as  having an HIV RNA 
level >1000 copies/ml.97 Time to viral rebound (years) was defined as the time from viral 
suppression to the time of the first rebound.  
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Statistical Analysis 
Descriptive statistics were produced to describe the study population by employing 
means, medians, standard deviations, and ranges to describe all continuous variables, and 
frequencies and percentages to describe all categorical variables. Independent two sample 
t-tests were used to detect differences in continuous variables, while chi-square tests were 
used to determine differences in categorical variables. 
For the analysis of time to event data in most epidemiologic studies, in particular 
HIV studies, the Cox proportional hazards model has become the model of choice, but it has 
been argued that parametric methods such as the Accelerated Failure Time (AFT) model 
may provide a more appropriate modeling framework.99,100 Advantages to employing 
parametric models are: 1) ability to use full maximum likelihood to estimate parameters; 2) 
the estimated coefficients can provide estimates that may be clinically meaningful; 3) 
estimates of survival time can be provided from fitted values from the model; and 4) 
residuals can be computed as differences between observed and predicted values of 
time.100,101  To determine the impact retention has on time to viral suppression as well as 
viral rebound, parametric methods were employed.  
 In the time to event analysis for VL suppression, time was measured from the start 
of HAART and analysis time ended at the earliest date of a suppressed VL or the end of the 
study period or death. Those individuals who did not achieve VL suppression or died were 
censored at the end of the study. For time to VL rebound, time was measured from the date 
of first suppressed VL and analysis time ended at the earliest date of a VL rebound or the 
end of the study period or death. Those individuals that did not achieve a rebound were 
censored from the analysis. The Kaplan-Meier method was used to produce plots to provide 
useful information about the shape of the hazard function and the plots were used to also 
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determine whether the hazard function could be modeled using a parametric form. The log-
survival and log-log survival plots were also produced to determine the appropriateness of 
a Weibull or Exponential distribution. Kaplan-Meier estimates were plotted overall and 
stratified by retention in care. For VL suppression, Wilcoxon tests were used to determine 
differences in survival curves between the retention groups and other covariates because it 
was assumed a priori that events would occur at earlier times and this test places more 
emphasis on the information at the beginning of the curves where the number at ‘risk’ is 
large.100,101 For VL rebound, log rank tests were used to determine differences in survival 
curves.  Producing Kaplan-Meier survival curves for all covariates of interest, we were able 
to obtain initial insight into the survival functions, which assisted in determining violation 
of the proportional hazards.100    
  The primary objective was not to determine just the risk of VL suppression, but to 
determine how early retention impacted time to VL suppression. Parametric survival 
models, in particular AFT models, were considered for the current analysis because the 
acceleration factor allows us to evaluate the effect of the predictor variables (retention) on 
the survival time as opposed to the hazard like the proportional hazard models.100,101  Four 
parametric models were considered for this analysis (Exponential, Weibull, Log-Logistic, 
and Log-normal). All four models were fitted to the observed data and graphical evaluation 
of each parametric assumption was done which involved plotting the transformation of the 
Kaplan-Meier estimates against the log of time. If the plots produced a straight line, the 
parametric assumption was not violated.  
 To determine which parametric model was a better fit to the data, likelihood ratio 
tests were used to compare models which are nested within each other (i.e. Exponential, 
Weibull, and Lognormal) and Akaike Information Criteria (AIC) was used to compare the 
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models that were not nested within each other. Although one model may have a lower AIC 
compared to the other parametric models, Cox-Snell residual plots were produced to 
determine absolute goodness of fit for each model.  
 For time to VL suppression, the parametric model with the lowest AIC appeared to 
be the log-normal model. The Cox-Snell residual plot (Figure 5.2) presented a straight line 
suggesting the log-normal model was a good fit to the data. Variables with a p-value ≤0.15 in 
the univariate analysis were considered for inclusion into the final model. To determine 
how retention in care impacted time to viral suppression, the model controlled for 
insurance status, race,  CD4+ cell counts at baseline, VL at baseline (log copies), income, 
history of AIDS, and year of HIV diagnosis. Time ratios were the measures of association for 
this analysis.   
 The same methods were used for observing time to VL rebound and the parametric 
model that appeared to have the better fit was the log-normal distribution (Figure 5.3). 
Time ratios (TR) were calculated for all variables included in the univariate and 
multivariate analysis. Variables with p-values ≤0.15 in the univariate analysis and those 
variables observed as confounders from previous literature were included in the 
multivariate analyses. The final model included retention in care, race, insurance status, 
history of AIDS, Hepatitis C, and an interaction between baseline VL and baseline CD4+ cell 
counts. 
All data were analyzed using SAS version 9.3 (Cary, NC) and p-values <0.05 were 
regarded as statistically significant. 
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Results 
Demographic Characteristics  
For the study sample (n = 1,166), the mean age at the start of HAART was 39.0 years 
(STD = 9.8). The majority of the patients were men (81.2%) and white non-Hispanic 
(70.9%). The reported mode of transmission among the patients was MSM (58.2%), a large 
percentage of patients were employed (44.9%), but almost half of the patients were living 
below the federal poverty level (49.8%) (Table 5.1). 
At the start of the study, approximately 40% of the patients did not have any form of 
insurance; with 33.3% having some form of public assistance (Medicaid or Medicare). 
Approximately 45% of the patients had an initial CD4+ cell count <200 cells/µL and the 
mean log VL was 6.26 (3.01) copies. At the end of the study period, only 51.5% of the 
patients were optimally retained in care (Table 5.1). For the entire sample, 64% had 
achieved a suppressed VL during the study period (data not shown). 
 There were 549 (47%) patients that had a VL >50 copies/ml at the initiation of 
HAART and were followed to observe viral suppression. Of these, 275 (50.1%) patients 
achieved a viral suppression at least once during the study period. Those with a suppressed 
VL were more likely to be white non-Hispanic (76.4% versus 63.1%, p = 0.001), and those 
living above the federal poverty level (43.6% versus 29.6%, p = 0.001) (Table 5.2).  
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 Clinically, those with a suppressed VL were more likely to have private insurance 
(29.9% versus 20.8%, p <0.0001) and Medicare (18.6% versus 7.7%, p <0.0001), an initial 
CD4+ cell count >350 cells/μL (44.0% versus 11.3%, p <0.0001), and more likely to have a 
lower mean log VL at initiation (8.4 copies versus 9.4 copies, p<0.0001). Viral suppression 
was also found to be more likely in those patients that optimally retained in care 
throughout the study period (62.6% versus 47.1%, p =0.0003) (Table 5.2). 
 At any time during the study period, 699 (60%) patients had achieved a viral 
suppression and were followed to observe a rebound. Of the 699 patients that achieved a VL 
suppression, approximately 22% (n=153) had a viral rebound during the course of the 
study. Those with a VL rebound were more likely to be those living below the poverty level 
(59.5% versus 43.6%, p = 0.001), and those with no insurance (39.2% versus 31.6%, p 
=0.003) or those on Medicaid (19.6% versus 14.4%, p=0.003). Clinically, viral rebound was 
significantly more likely to occur among those with a history of AIDS (69.9% versus 54.4%, 
p = 0.001), those with a history of Hepatitis C (18.3% versus 11.5%, p = 0.00), and those 
who were non-optimal retainers (59.5% versus 42.9%, p = 0.0003) (Table 5.2). 
Time to Viral Suppression 
 Figure 5.4 presents the Kaplan-Meier curve for the 275 patients that achieved a viral 
suppression, with those patients who did not being censored (n = 274). The curve suggests 
a faster progression within the first year of initiation to HAART, followed by a much slower 
progression as time increases. The median time to viral suppression for the patients was 
approximately 5 years. Figure 5.5 presents a Kaplan-Meier curve of time to viral 
suppression stratified by retention. The curve suggests that the patients who were 
optimally retained in HIV medical care after the initiation of HAART had a shorter time to 
viral suppression compared to those who were not optimally retained in care. The median 
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time to viral suppression for optimal and non-optimal retainers was 2.5 and 6.5 years, 
respectively (Wilcoxon test, p <0.0001). The estimated cumulative survival distribution for 
the log-normal distribution was produced for optimal and non-optimal retainers. The 
curves, show results similar to the Kaplan-Meier curves, that optimal retainers have a 
higher chance of viral suppression compared to the non-optimal retainers (Figure 5.6). 
 In the log-normal models, the association with viral suppression was tested for all 
variables in the univariate models and those with a p-value <0.15 in the unadjusted model 
were included in the adjusted model. In the unadjusted log-normal model, non-whites, 
those with no insurance or Medicaid, those with an AIDS diagnosis, and higher baseline VLs, 
had longer times to viral suppression compared to their counterparts (Table 5.3). 
Controlling for insurance status, race, baseline CD4+ cell counts, and baseline VLs, the 
expected time to viral suppression for non-optimal retainers was 1.94 (95% CI: 1.37, 2.77)  
times greater than those who optimally retained in care. The expected time to viral 
suppression for those with no insurance was 1.68 (95% CI: 1.06, 2.68) times greater 
compared to those with private insurance, and those with higher baseline VL had a longer 
time to viral suppression (TR=1.11; 95% CI: 1.04, 1.19) (Table 5.3). 
Time to Viral Rebound 
 The Kaplan-Meier curve for the 153 patients that experienced a viral rebound is 
presented in Figure 5.7.  The figure appears to show a slow progression to viral rebound, 
and the mean time to rebound among the 153 patients was approximately 7 years. 
Stratified by retention in care, figures 5.8 and 5.9 shows the Kaplan-Meier curve and the 
estimated cumulative incidence curves for time to rebound curves for the lognormal 
distribution, respectively.  The curves presented suggest that within the first few years of 
achieving viral suppression, the time to rebound is similar between the groups, but as time 
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progresses, individuals not optimally retained in care, have shorter time to rebound (Log 
Rank test, p = 0.013). 
 A log-normal regression model was chosen to determine the association between 
specific variables and time to viral rebound. Variables with a Log Rank test p-value ≤0.15 
were initially included in the regression model. In the unadjusted analysis, retention in care, 
insurance status, AIDS diagnosis, Hepatitis C, CD4+ cell counts, VL were all associated with 
time to viral rebound (Table 5.4). Controlling for these variables, the expected time to viral 
rebound for those patients who were not optimally retained in care was 0.59 (95% CI: 0.38, 
0.92) times shorter compared to those who were optimally retained. Compared to patients 
with private insurance, patients with no insurance or Medicaid had much shorter times to 
viral rebound at 0.42 (95% CI: 0.23, 0.76) and 0.42 (95% CI: 0.21, 0.83) times, respectively. 
There were no significant interactions with retention in care, but there was a significant 
interaction between baseline CD4+ cell count and baseline VL. As the baseline VL increases 
by one unit for patients with a baseline CD4+ cell count <200 cells/µL, the estimated time to 
viral rebound was 1.18 (95% CI: 1.00, 1.40) times longer compared to those with a baseline 
CD4+ cell count >200 cells/µL (Table 5.4). This result further suggests that individuals with 
a stable clinical status (‘healthier’) have worse outcomes compared to those entering care 
with much severe disease status.  
Discussion 
 The purpose of this study was to understand the effect retention in care had on viral 
suppression and viral rebound among individuals receiving HAART. There is a paucity of 
research on the examination of the effect of retention in HIV medical care on time to viral 
suppression, and to our knowledge, this is one of the first studies to observe the impact 
retention has on viral rebound. For time to viral suppression, we selected a small cohort of 
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patients who were initiating HAART for the first time and followed them from the time of 
HAART initiation to the time of their first suppressed VL. Retention in care was shown to be 
associated with time to viral suppression. Patients that had optimal (100%) retention after 
initiating HAART were more successful at achieving a suppressed VL and the time it took to 
suppression was much shorter than the patients who were poorly retained in care. The 
results from our study are consistent with those of Mugavero et al, which observed the 
impact early retention (number of missed visits in the first year of care) had on viral 
suppression, and they were able to show that patients with perfect visit adherence were 
more likely to have a viral suppression, and that each “no show” clinic visit conveyed a 17% 
increased risk of delayed viral suppression.24 
 The results of the current study convey important implications for individual 
patient outcomes as well as future public health prevention efforts. Failure to achieve viral 
suppression in a timely manner and maintain a suppressed VL can be damaging to the 
individual’s health; the longer it takes for an individual living with HIV to suppress their VL, 
the risk of detrimental clinical events increases. Researchers have suggested that failure to 
suppress one’s VL can be an indicator of poor medication adherence as well as medication 
resistance.12,85,95  
From a public health standpoint, failure to achieve viral suppression can be 
damaging to prevention efforts, as patients with high VLs may increase the risk of HIV 
transmission. In 2008, Metsch et al conducted a study to show how recently diagnosed 
patients with optimal early retention in care had reductions in sexual risk behaviors 
compared to those who were poorly retained.31 We were able to show that poor retention in 
HIV care, among individuals who had initiated HAART, was a barrier for timely viral 
suppression, which in turn impedes the potential reduction of transmission of HIV to others. 
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This shows the importance of retention in care among individuals living with HIV and 
strategies should be developed to help re-engage those individuals who have fallen out of 
care as this can improve their chances of viral suppression.  
  Retention in care was also shown to be an important factor in an individuals’ ability 
to maintain viral suppression after achieving their first suppressed VL. Of the 699 patients 
with a suppressed viral load at any time during the study period, approximately 22% 
rebounded back to a VL >1000 copies/ml and approximately 60% of the patients that 
rebounded had poor retention. The percentage of rebounders in our study is similar to 
other studies which observed VL rebound, ranging from 18% to 40%, but our study is 
unique as we observed the impact retention in care had on those who had a viral 
rebound.96-98 The results of the study suggested that patients with optimal retention were 
more likely to prevent or at least prolong the time to a viral rebound. This is important as 
individuals who rebound after viral suppression suggest poor medication adherence as well 
as possible medication resistance, which typically leads to the stoppage of the specific drug 
class. This study notes the importance of retention in care even after the patient has 
achieved viral suppression. Once suppression has been achieved, the patient should still be 
retained in care and medication adherence should be monitored to prevent future viral 
rebound.  
 The patients in the study with no insurance or Medicaid had challenges in achieving 
timely viral suppression and prolonging viral rebound once VLs had been suppressed. Even 
when controlling for the other variables in the parametric models, patients with no 
insurance had delays in viral suppression and once VLs were suppressed they had shorter 
times to viral rebound. The cohort selected comes from a Ryan White funded clinic which 
means that there are opportunities available for individuals who are uninsured and may not 
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have resources to obtain their medications. This group of patients also had difficulties in 
retaining in care, which could explain why they did not suppress their VLs after initiation of 
HAART in a timely manner.  
Patients on Medicaid were also more likely to acquire a viral rebound compared to 
those with private insurance. This is an interesting finding, as individuals on Medicaid can 
obtain medications and care for no charge. The Medicaid population has been consistently 
shown by researchers to be poor retainers in care, poor viral suppressers, and viral 
rebounders.40,52,55 Studies should be conducted on this population to get a better sense of 
why retention is poor which can then lead to poor HIV outcomes. Understanding the factors 
that prevent this population from retaining in care and suppressing VLs can help guide 
future prevention efforts to re-engage this population back into care.  
 Monitoring patients living with HIV is important and care should be consistent 
before and after patients initiate HAART. We were able to show that patients with low CD4+ 
cell counts and high VLs at the time of initiation were more likely to delay viral suppression, 
and once suppressed, were more likely to progress to a viral rebound in a much shorter 
time period. Our results are consistent with other studies that have observed viral 
suppression and rebound.24,97,98  
There is still the debate as to when a patient should start HAART based on their 
CD4+ cell count.12 It appears that prescribing HAART at lower CD4+ cell counts in this 
population may be detrimental to the patients’ health, but this shows the importance of 
maintaining consistent monitoring of these patients and making sure that they are engaged 
in care. Maintaining optimal retention among this cohort can lead to monitoring of 
medication adherence as well as referring to important ancillary services to help with 
treatment adherence and receipt of prescribed medications. 
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 This study was an observational, retrospective cohort study and subject to potential 
uncontrolled confounders for which we had no information, such as alcohol use and 
presence of social and familial support networks. A medical chart review was employed to 
capture patient data and not all patients had complete information in their medical records. 
This was the case for selecting patients for inclusion into the study who had a VL and a 
follow-up measurement; 193 patients were excluded from the analysis partly because they 
had missing information regarding their HIV labs (e.g. VL recorded but no date, or a VL date 
but no VL result). There were no significant differences between those that were excluded 
from the analysis, but exclusion of subjects reduces the power of the study and potentially 
introduces bias. Although the BCC provides care for a large proportion of individuals 
diagnosed with HIV who reside in central and eastern KY, the results may not be 
generalizable to all Kentuckians living with HIV nor all individuals living with HIV in the 
United States. A future research study conducted using similar methods should involve a 
multi-center study across all Ryan White funded clinics in KY. 
Finally, medication adherence was not observed or evaluated for this study. Studies 
have observed the impact medication adherence has on viral suppression as well as viral 
rebound, and have suggested that patients that are not at least 95% adherent to their 
medications are more likely to have virological failures. Medication adherence is on the 
causal pathway between retention in care and VL suppression/rebound, but the purpose of 
this study was to establish the relationship between retention and VL suppression and 
rebound.19 It may be concluded that medication adherence is the driving force behind viral 
suppression, but Giordano et al were able to show that poor retention in care and poor 
medication adherence were highly correlated therefore it seemed appropriate to use 
retention in care as a surrogate measure.85 Also with this study, obtaining medication 
adherence was difficult as the patient population at the BCC obtain their medications from 
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multiple pharmacies, which makes it difficult to track medication pick up once the 
prescription has been written. If there was a centralized pharmacy available for this 
population, medication adherence could be evaluated more accurately. The retention in 
care measurements were subject to very little if any measurement error, since our medical 
records on patient clinic visits were excellent. 
Conclusion 
 In conclusion, we were able to identify significant associations between retention in 
care and viral suppression/rebound among patients initiating HAART. Patients who were 
poorly retained in care after initiating HAART prolonged their opportunity to achieve viral 
suppression compared to optimal retainers in care. And, once the VL was suppressed, poor 
retainers had shorter times to viral rebound compared to optimal retainers in HIV medical 
care. The results of this study stress the importance of maintaining optimal retention among 
individuals living with HIV in order to increase the number of individuals with suppressed 
VLs. Researchers should continue to study the impact of retention in HIV medical care on 
clinical outcomes and strategies to improve retention and re-engage those lost to follow-up 
back into care.  
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Table 5.1. Socio-demographic and Clinical Characteristics among 
Patients Initiating HAART 
 
Total                                                                           
n (%) 
Total 1166 (100) 
Sex 
 Female 219 (18.8) 
Male 947 (81.2) 
Race 
 Non-White 339 (29.1) 
White 827 (70.9) 
Age at HAART 
 ≤24 yrs 89 (7.6) 
25 - 34 yrs 294 (25.2) 
35 - 44 yrs 453 (38.9) 
>44 yrs 330 (28.3) 
Age mean yrs (std) 39.0 (9.8) 
Mode of Transmission 
 Heterosexual 328 (28.2) 
IDU 100 (8.6) 
Other 59 (5.1) 
MSM 678 (58.2) 
Employment Status 
 Employed 441 (44.9) 
Unemployed 350 (35.6) 
Other 191 (19.5) 
Poverty Level 
 Below 581 (49.8) 
Above 405 (34.7) 
Missing 180 (15.4) 
History of Tobacco Use 
 Yes 580 (49.7) 
No 586 (50.3) 
History of Illicit Drug 
Use 
 Yes 301 (25.8) 
No 865 (74.2) 
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Table 5.1. continued 
 
Total                                                                           
n(%) 
Insurance Type 
 No Insurance 465 (40.3) 
Medicaid 188 (16.3) 
Medicare 196 (17.0) 
Private 304 (26.4) 
History of AIDS Diagnosis 
 Yes 688 (59.0) 
No 478 (41.0) 
Hepatitis C 
 Yes 149 (12.8) 
No 1017 (87.2) 
Non-HIV related 
comorbidity 
 Yes 571 (49.0) 
No 595 (51.0) 
Baseline CD4+ Cell Counts 
 <200 359 (44.8) 
200 - 350 142 (15.7) 
>350 406 (34.8) 
Baseline CD4+ Cell Counts - 
Median (min, max) 322 (1.0, 1696) 
Baseline Viral Load mean 
log copies (std) 6.69 (3.10) 
Retention 
 Optimal 601 (51.5) 
Non Optimal 565 (48.5) 
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Table 5.2. Associations of Socio-Demographic and Clinical Characteristics and Viral 
Suppression and Rebound among the Patients Seeking HIV Medical Care and Initiating 
HAART 
 
Viral Suppression                       
(n = 549) 
 
Viral Rebound                          
(n = 699) 
 
  
Yes                 
n (%) 
No                
n (%) p 
Yes              
n (%) 
No                
n (%) p 
Total 275 (50.1) 274 (49.9) 
 
153 (21.9) 546 (78.1) 
 Sex 
      Female 52 (18.9) 58 (21.2) 0.51 32 (20.9) 90 (16.5) 0.2 
Male 223 (81.1) 216 (78.8) 
 
121 (79.1) 456 (83.5) 
 Race 
      Non-White 65 (23.6) 101 (36.9) 0.001 41 (26.8) 117 (21.4) 0.16 
White 210 (76.4) 173 (63.1) 
 
112 (73.2) 429 (78.6) 
 Age at 
HAART 
      ≤24 yrs 20 (7.3) 19 (6.9) 0.20 5 (3.3) 20 (3.7) 0.28 
25 - 34 yrs 67 (24.4) 89 (32.5) 
 
38 (24.8) 107 (19.6) 
 35 - 44 yrs 13 (41.1) 103 (37.6) 
 
65 (42.5) 217 (39.7) 
 >44 yrs 75 (27.3) 63 (23.0) 
 
45 (29.4) 202 (37.0) 
 Age mean yrs 
(std) 38.9 (9.6) 37.7 (9.3) 0.14 39.2 (9.0) 40.3 (9.7) 0.18 
Mode of 
Transmission 
      Heterosexual 75 (27.3) 85 (31.1) 0.69 43 (28.1) 150 (27.5) 0.33 
IDU 26 (9.5) 22 (8.1) 
 
16 (10.5) 46 (8.4) 
 Other 10 (3.6) 12 (4.4) 
 
11 (7.2) 23 (4.2) 
 MSM 164 (59.6) 154 (56.4) 
 
83 (54.3) 327 (59.9) 
 Employment Status 
     Employed 109 (45.0) 106 (47.3) 0.04 54 (38.6) 220 (46.5) 0.2 
Unemployed 78 (32.2) 87 (38.8) 
 
54 (38.6) 149 (31.5) 
 Other 55 (22.7) 31 (13.8) 
 
32 (22.9) 104 (22.0) 
 Poverty Level 
      Below 135 (49.1) 154 (56.2) 0.001 91 (59.5) 238 (43.6) 0.001 
Above 120 (43.6) 81 (29.6) 
 
52 (34.0) 226 (41.4) 
 Missing 20 (7.3) 39 (14.2) 
 
10 (6.5) 82 (15.0) 
 History of 
Tobacco Use 
      Yes 150 (54.6) 143 (52.2) 0.58 86 (56.2) 265 (48.5) 0.09 
No 125 (45.5) 131 (47.8) 
 
67 (43.8) 281 (51.5) 
 History of 
Illicit Drug 
Use 
      Yes 86 (31.3) 86 (31.4) 0.98 29 (19.0) 127 (23.3) 0.26 
       
No 189 (68.7) 188 (68.6)   124 (81.1) 419 (76.7)   
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Table 5.2. continued 
 
Viral Suppression 
 
Viral Rebound 
 
  
Yes                 
n (%) 
No                
n (%) p 
Yes              
n (%) 
No                
n (%) p 
Insurance 
Type 
      No Insurance 108 (39.4) 145 (52.9) <0.001 60 (39.2) 171 (31.6) 0.003 
Medicaid 33 (12.0) 51 (18.6) 
 
30 (19.6) 78 (14.4) 
 Medicare 51 (18.6) 21 (7.7) 
 
37 (24.2) 119 (22.0) 
 Private 82 (29.9) 57 (20.8) 
 
26 (17.0) 174 (32.1) 
 History of 
AIDS 
Diagnosis 
      
Yes 165 (60.0) 184 (67.2) 0.08 
107 
(69.9) 297 (54.4) 0.001 
No 110 (40.0) 90 (32.9) 
 
46 (30.1) 249 (45.6) 
 Hepatitis C 
      Yes 38 (13.8) 37 (13.5) 0.91 28 (18.3) 63 (11.5) 0.03 
No 237 (86.5) 237 (86.2) 
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(81.7) 483 (88.5) 
 Non-HIV 
related 
comorbidity 
      Yes 143 (52.0) 120 (43.8) 0.05 99 (64.7) 300 (55.0) 0.03 
No 132 (48.0) 154 (56.2) 
 
54 (35.3) 246 (45.1) 
 Baseline CD4+ Cell 
Counts 
     <200 100 (36.4) 131 (47.8) <0.001 36 (23.5) 126 (23.1) 0.06 
200 - 350 53 (19.3) 22 (8.0) 
 
30 (19.6) 88 (16.1) 
 >350 121 (44.0) 31 (11.3) 
 
84 (54.9) 289 (52.9) 
 Missing 1 (0.4) 90 (32.9) 
 
3 (2.0) 43 (7.9) 
 Baseline 
Viral Load 
mean log 
copies (std) 8.4 (2.8) 9.4 (2.5) <0.001 5.7 (2.67) 5.8 (2.9) 0.89 
Early 
Retention 
      Optimal 172 (62.6) 129 (47.1) <0.001 62 (40.5) 312 (57.1) <0.001 
Non Optimal 103 (37.5) 145 (52.9)   91 (59.5) 234 (42.9)   
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Table 5.3 Log-normal Regression Determining the Association between Retention in 
HIV Medical Care and Time to Viral Suppression 
 
Unadjusted 
TRa 
95% CIb Adjusted 
TR 
95% CI 
Variables         
Retention 
    Non Optimal vs. Optimal 2.31 (1.62, 3.31)ǂ 1.94 (1.37, 2.77)ǂ 
Race 
    Non-White vs. White 1.69 (1.13, 2.52)* 1.34 (0.91,2.00) 
Insurance Status 
        No Insurance vs. Private 1.70 (1.09, 2.64)* 1.68 (1.06, 2.68)* 
Medicaid vs. Private 2.15 (1.19, 3.89)* 1.56 (0.83, 2.94) 
Medicare vs. Private 0.97 (0.54, 1.74) 0.82 (0.46, 1.46) 
Poverty Level     
Above vs. Below 0.68 (0.41, 0.99)* 1.02 (0.67, 1.55) 
Baseline CD4+ Cell 
Counts (per 100 
cells/µL) 0.84 (0.79, 0.91)ǂ 0.89 (0.81, 0.97)ǂ 
AIDS Diagnosis  
    Yes vs. No 1.86 (1.29, 2.68)† 1.23 (0.79, 1.91) 
Baseline Viral Load (per 
log copy/ml) 1.11 (1.04, 1.19)† 1.11 (1.04, 1.19)† 
a TR = Time Ratio 
    b CI = Confidence Interval 
    ǂ p-value <0.0001 
    † p-value <0.01 
    * p-value <0.05 
    Note: The Regression model adjusted for the year of HIV 
diagnosis 
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Table 5.4 Log-normal Regression Determining the Association 
between Retention in HIV Medical Care and Time to Viral 
Rebound 
 
Adjusted TR 95% CI 
Variables     
Retention 
  Non Optimal vs. Optimal 0.59 (0.38, 0.92) 
Race 
  Non-White vs. White  0.72 (0.43, 1.19) 
Insurance Status 
  No Insurance vs. Private 0.42 (0.23, 0.76)
† 
Medicaid vs. Private 0.42 (0.21, 0.83)
† 
Medicare vs. Private 0.56 (0.30, 1.05) 
AIDS Diagnosis 
  Yes vs. No 0.47 (0.28, 0.77)* 
Hepatitis C 
  Yes vs. No 1.23 (0.68, 2.24) 
Baseline Viral Load 
  Baseline CD4+ Cell Count <200 1.18 (1.00, 1.40)* 
Baseline CD4+ Cell Count >200 
  a TR = Time Ratio 
  b CI = Confidence Interval 
  ǂ p-value <0.0001 
  † p-value <0.01 
  * p-value <0.05 
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  1166 Patients 
initiated HAART and 
were eligible for the 
study 
1108 Patients had at 
least one viral load 
recorded 
58 Patients 
removed due 
to no viral 
load result 
recorded 
973 Patients included 
in the study 
135 Patients 
removed due to 
no date for viral 
loads recorded 
699 patients had at 
least one VL <50 
copies/ml 
274 Patients did not 
achieve a suppressed 
viral load 
274 Patients 
did not achieve 
a suppressed 
viral load 
549 Patients 
had a viral 
load >50 at the 
time of HAART 
initiation 
275 Patients 
achieved a 
suppressed 
viral load 
153 Patients 
had a viral load 
rebound 
546 did not have 
a viral rebound 
Figure 5.1 Flow chart of the Patients Enrolled in the Study 
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Figure 5.2 Cumulative Hazard Plot of the Cox-Snell Residual for the 
Log-Normal Model Determining Time to Viral Suppression 
Figure 5.3 Cumulative Hazard Plot of the Cox-Snell Residual for the 
Log-Normal Model Determining Time to Viral Rebound 
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Figure 5.4 Kaplan-Meier Curve for the Time to Viral Suppression 
Figure 5.5 Kaplan-Meier Curves for the Time to Viral Suppression 
Stratified by Optimal Retention 
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Figure 5.6 Estimated Cumulative Incidence Curves for time to viral suppression for the 
Log-Normal distribution  
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Figure 5.7 Kaplan-Meier Curves for Time to Viral Rebound 
Figure 5.8 Kaplan-Meier Curves for Time to Viral Rebound Stratified by 
Optimal Retention 
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Figure 5.9 Estimated Cumulative Incidence Curves for time to viral rebound for the Log-
Normal distribution 
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Chapter Six 
Discussion and Conclusion 
 This chapter provides a summary and discussion of the conclusions of the five 
previous chapters. This chapter also discusses the individual and public health implications, 
the strengths and limitations of this research, and recommendations for future research. 
There were four papers presented in this dissertation: (1) Measuring Retention in HIV 
Medical Care: A Literature Review; (2) “A Comparison Study of Methods for Measuring 
Retention in HIV Medical Care”; (3) “Impact of non-HIV Related Comorbidities on Retention 
in HIV Medical Care: Does Retention Improve over Time”; and (4) “Impact of Retention in 
HIV Medical Care on Time to Viral Load Suppression and Rebound among Individuals 
Initiating HAART.” 
 The first paper (Chapter Two) was a comprehensive literature review that focused 
on the methods used in measuring retention, their advantages and disadvantages, and their 
predictors. The purpose of the review was to provide the reader with a framework of how 
the retention measures have been conducted in studies and what resources are needed to 
evaluate retention. The review showed that there were at least five different ways to 
measure retention in care among individuals living with HIV. The five measures were visit 
constancy, gaps in care, missed visits, visit adherence, and the HRSA performance 
measure15. The choice of a retention measure may depend on the data and resources 
available to the clinicians or researchers15. The retention studies, regardless of the measure 
used, show that in general, approximately 60% of patients were actually retaining in care 
and the predictors observed were similar, regardless of the time period13. Currently, there 
has no study to suggest which retention measure should is preferred.  
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 In chapter three, the purpose was to measure retention in HIV medical care by 
employing three measurement techniques (visit constancy, gaps in care, and the HRSA 
performance measure). The three techniques were compared, using ROCs, to determine 
which methods most accurately discerned between those patients with and without a viral 
suppression or CD4+ cell count failure. The patients included in the study were followed for 
an average of 5 years and the average retention was approximately 77.6% and 77.2% for 
visit constancy and the HRSA performance measure, respectively. The average time 
between two consecutive visits was 8 months. Calculating and comparing the AUCs among 
the three measures, visit constancy appeared to be the best measure in predicting viral 
suppression as it had the highest AUC. The logistic regression performed in this study 
showed that there was a dose-response in regards to the impact retention had on achieving 
viral suppression. Patients who were suboptimal, sporadic, or poor retainers had much 
lower odds of achieving viral suppression compared to those with 100% retention 
(optimal). 
Currently there is no preferred method for defining retention in care as multiple 
methods have been used in the research, but the purpose of this study was to determine 
which method may be the most appropriate measure as this could help clinicians and 
researchers to be more consistent in choosing a measurement. Having consistency in the 
way retention is measured increases the ability to accurately compare across research 
studies. 
 Chapter Four focused on the predictors of retention in HIV medical care as well as 
how non-HIV related comorbidities impacted retention over time. There have been 
inconsistent results on how comorbidities like mental health disorders impact retention in 
care. This study was one of the first studies to observe how multiple comorbidities 
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diagnosed during the course of infection impacted retention over time. The 1,358 patients 
included in the study were followed in 6-month intervals to determine the number of clinic 
visits completed and the diagnoses of any comorbidity or other infections. There were 
seven comorbidities observed in this study (cardiovascular, cerebrovascular, diabetes, 
mental health, respiratory, cancer, and renal). Using visit constancy as the retention 
measure of choice, the patients were categorized into four groups: optimal retainers, 
suboptimal retainers, sporadic retainers, and poor retainers. 
 Only 48.6% of the patients included in the study had optimal retention throughout 
the entire study. It was also shown retention decreased over time for the cohort, especially 
for those who did not have any comorbidity or other illnesses. A GLMM was employed to 
show that patients with one or more comorbidities diagnosed throughout the study period 
had improved retention over time. Looking at each comorbid condition separately, patients 
with diabetes, cancer, cardiovascular, and depression conditions had improved retention 
over time compared to their counterparts. It was also shown that non-whites, those with an 
ADI, those with Hepatitis C, and those with no insurance or Medicaid had worse retention 
over time compared to their counterparts.  
 Chapter Five focused on how retention in care impacted time to viral suppression 
and viral rebound among individuals who initiated HAART. There were 1,166 patients that 
had initiated HAART during the study period, and were followed from the time of HAART 
initiation until the time of viral suppression. This study was conducted because little is 
known on how retention in care impacts the time to viral suppression and rebound among 
those who are poorly retained in care.  
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It was shown that individuals who retained in care after initiation of HAART were 
more likely to achieve viral suppression and had a shorter time to progression compared to 
those who did not optimally retain in care. It was also shown that among those who 
achieved a viral suppression, optimal retention prolonged the risk of viral rebound. 
Implications 
 The results from these studies have major implications for the individuals living 
with HIV as well as public health efforts.  The results are consistent with other studies 
conducted. It is important to note how important retention in care is on the health of an 
individual living with HIV. It was shown that individuals poorly retained in care had 
prolonged times to viral suppression and increased risk of viral rebound once suppression 
had been achieved. This is important, as viral suppression is typically used as a surrogate 
measure for determining HIV management success as well as medication adherence. 
Individuals not retaining in care continuously are missing opportunities for accessing 
treatment benefits and increasing their risk for medication resistance, progression to AIDS, 
and death. 
 From a public health perspective, poorly retained HIV infected individuals can 
hinder the process in reducing the incidence of HIV in Kentucky as well as in the U.S. It is 
estimated that approximately 50,000 people are infected with HIV each year in the U.S., and 
researchers have suggested the use of retention and engagement in HIV care as a 
prevention tool to reduce this statistic.11,12,72 
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 It has been shown that optimal retention in care can reduce risky sexual behaviors 
and even reduce the risk of HIV transmission. These study results clearly showed that 
optimally retaining in care increases viral suppression and reduces risk of viral failure. If we 
can engage all individuals living with HIV in continuous care, the burden of VL will be 
decreased and the chances of transmission will be reduce.  
Strengths and Limitations 
 A major strength of these studies is the comparatively long study period (9 years). 
The average follow-up time for the patients included in the study was approximately 5 
years, which allowed for evaluation of retention over time. The dissertation adds to the 
current literature by comparing multiple measures of retention and using an extended time 
period to assess the effects of retention in care over time.  
 The study population observed in this study was patients who sought care at a RW 
funded clinic (BCC) in Lexington, Kentucky. The BCC is home to approximately 2,000 active 
patients and a large percentage of those seeking care at the clinic are from rural areas in 
Kentucky, the findings may not be generalizable to all individuals living with HIV/AIDS who 
are seeking medical care in Kentucky or in the U.S. There may be significant differences, 
other than insurance and income status, between those seeking care in RW funded clinics 
and those seeking care in private clinics in Kentucky. Currently no studies have compared 
RW funded clinics with other HIV care clinics in the U.S. 
The studies conducted in this dissertation were retrospective cohort studies, which 
employed a medical chart review. Uncontrolled confounders may exist for which no 
information was available. Medical charts are not designed for research purposes and 
information was incomplete for some (or most) of the patients seeking care; this was the 
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case for demographic information like education and income. Also VLs and CD4+ cell counts 
were missing for a number of patients that sought care at the BCC; therefore they could not 
be included in some of the study analyses. Although there were no major differences 
between the groups excluded and included from the analyses, other than the fact that those 
excluded were not on HAART, those that were excluded reduced the power of the study to 
observe differences across groups and may have introduced biases.  
As noted in Chapter Two, there are at least five ways to measure retention in HIV 
medical care (visit constancy, HRSA performance measure, visit adherence, missed visits, 
and gaps in care), but only three of the five measurements were evaluated in this 
dissertation. A limitation is that visit adherence and missed visits were not evaluated and 
compared to the other three measures, in part because missed clinic visits were not 
captured in the medical charts. In order to determine the number of visits that were missed 
and calculate visit adherence, a system must be in place to capture that information. It is 
important that in order to make a complete recommendation on the measure of retention 
that most appropriately defines a poor or optimal retainer, all measures of retention must 
be evaluated and compared in future studies.  
Future Research 
 Retention in medical care among individuals living with HIV should be given major 
attention as those who are optimally retained in care have been consistently shown to 
achieve more favorable outcomes, like viral suppression, compared to those who are not 
optimally retained in care. Although researchers have consistently shown the negative 
impact poor retention has on health outcomes, more research still needs to be conducted in 
this area. First, it is important for clinicians and researchers to adopt one measurement of 
retention and use it consistently throughout studies, which can make comparison of studies 
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easier. A guideline should be set which states what constitutes poor or optimal retention 
and what measure should be used to determine retention (i.e. missed visits, visit constancy, 
HRSA, etc.).  
Chapter Three provided a recommendation to help clinicians and researchers 
determine which measure may appropriately define retention, but not all measurements 
could be evaluated in the study due to the resources available, so future studies should be 
conducted where all measures of retention can be compared to have a recommended 
retention measure set in place.  
 It is important for researchers to understand the factors that may impact retention 
that go beyond the normal socio-demographic and clinical characteristics, as this may help 
HIV clinicians and researchers develop interventions that can help reduce the barriers to 
optimal retention. For example, referring patients to service organizations that may assist 
with transportation or housing can be beneficial in increasing retention among this 
population. Providing treatment referrals or behavioral interventions to patients with 
substance abuse disorders may be beneficial to the patient who is seeking HIV medical care. 
There is limited published data that suggests which interventions are most effective at 
maintaining optimal retention, and which interventions work for specific groups. Some 
researchers have suggested that care coordination, which links patients to an individual 
(e.g. case manager or social worker) once they have initiated care, may help the patient 
better navigate the healthcare system which in turn helps them maintain consistent contact 
with their medical provider.53-55 Researchers need to publish and share their work, so other 
researchers interested in providing interventions can replicate their study. Also studies 
need to be conducted that randomizes patients into different intervention strategies to see 
which strategy may work best in keeping patients retained in care.  
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A longitudinal assessment of retention is urgently needed as most studies have 
typically restricted their time to one to three years. It is important to understand how 
retention changes over time and incorporating a longitudinal study of retention will provide 
insight on who the individuals are that are falling out of care and insight into how these 
individuals may be re-engaged back into care. Resources and funding should be made 
available so longitudinal studies can be conducted and resources are needed to develop 
strategies to bring those who have fallen out of care back into care.14  
This dissertation focused on one single facility (BCC), which meant that the results 
could not be generalized to any other HIV population seeking medical care. Studies focusing 
on retention should consider multi-site studies especially within each state and nationally 
to determine overall retention. Clinicians and researchers, from multiple clinic sites, should 
be open to collaborating together. A future study in Kentucky will be to collaborate with the 
other RW funded clinics and determine retention and the barriers that impact optimal 
retention. It is also important to conduct multi-site studies within the state as patients may 
be in continuous care, but accessing care at different clinics. A patient seeking HIV medical 
care may change providers for numerous reasons, and having all clinics on board can 
ensure that the patient is actually considered an optimal retainer.  
Retention in care should remain a major priority for clinicians and researchers as 
this can improve the health of individuals living with HIV as well as potentially reduce the 
incidence of new infections. 
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